<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2679671-A1" country="EP" doc-number="2679671" kind="A1" date="20140101" family-id="29586960" file-reference-id="314654" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146549821" ucid="EP-2679671-A1"><document-id><country>EP</country><doc-number>2679671</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13186524-A" is-representative="NO"><document-id mxw-id="PAPP154823744" load-source="docdb" format="epo"><country>EP</country><doc-number>13186524</doc-number><kind>A</kind><date>20030527</date><lang>EN</lang></document-id><document-id mxw-id="PAPP187510446" load-source="docdb" format="original"><country>EP</country><doc-number>13186524.8</doc-number><date>20030527</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140454642" ucid="EP-03736723-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>03736723</doc-number><kind>A</kind><date>20030527</date></document-id></priority-claim><priority-claim mxw-id="PPC140453530" ucid="US-38261602-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>38261602</doc-number><kind>P</kind><date>20020524</date></document-id></priority-claim><priority-claim mxw-id="PPC140454442" ucid="US-44858503-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>44858503</doc-number><kind>P</kind><date>20030221</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1620477150" load-source="docdb">A61K  35/12        20150101A N20180629RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988097184" load-source="docdb">C12N   5/02        20060101ALI20131023BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988105249" load-source="docdb">C12N   5/0735      20100101A I20100814RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988108917" load-source="docdb">C12N   5/00        20060101AFI20131023BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988118799" load-source="docdb">C12N   5/073       20100101ALI20131023BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988119440" load-source="docdb">C12N   5/10        20060101ALI20131023BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988123806" load-source="docdb">C12N  15/873       20100101A I20100814RMEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1988105499" load-source="docdb" scheme="CPC">C12N2517/10        20130101 LA20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988114241" load-source="docdb" scheme="CPC">A61K  35/12        20130101 LA20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988118781" load-source="docdb" scheme="CPC">C12N  15/873       20130101 FI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988128472" load-source="docdb" scheme="CPC">C12N2510/00        20130101 LA20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988136719" load-source="docdb" scheme="CPC">C12N   5/0606      20130101 LI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132181947" lang="DE" load-source="patent-office">Eine Bank von Stammzellen zur Herstellung von Zellen für die Transplantation, die HLA-Antigene hat, die mit denen von Transplantationspatienten passen, und Verfahren zur Herstellung und Verwendung einer solchen Stammzell-Bank</invention-title><invention-title mxw-id="PT132181948" lang="EN" load-source="patent-office">A bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank</invention-title><invention-title mxw-id="PT132181949" lang="FR" load-source="patent-office">Une banque de cellules souches pour produire des cellules pour la transplantation ayant des antigènes HLA correspondant à ceux des greffés et des méthodes de fabrication et d'utilisation d'une telle banque de cellules souches</invention-title><citations><patent-citations><patcit mxw-id="PCIT377627551" load-source="docdb" ucid="US-0237899-W" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>0237899</doc-number><kind>W</kind><date>20021126</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377624570" load-source="docdb" ucid="US-0301827-W" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>0301827</doc-number><kind>W</kind><date>20030122</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377622959" load-source="docdb" ucid="US-11293902-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>11293902</doc-number><kind>A</kind><date>20020402</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377617038" load-source="docdb" ucid="US-19108900-P" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>19108900</doc-number><kind>P</kind><date>20000322</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377618264" load-source="docdb" ucid="US-22728202-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>22728202</doc-number><kind>A</kind><date>20020826</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377620144" load-source="docdb" ucid="US-41833302-P" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>41833302</doc-number><kind>P</kind><date>20021016</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377629787" load-source="docdb" ucid="US-52087900-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>52087900</doc-number><kind>A</kind><date>20000405</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377620151" load-source="docdb" ucid="US-52702600-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>52702600</doc-number><kind>A</kind><date>20000316</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653621" load-source="docdb" ucid="US-5464764-A"><document-id format="epo"><country>US</country><doc-number>5464764</doc-number><kind>A</kind><date>19951107</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653622" load-source="docdb" ucid="US-5612205-A"><document-id format="epo"><country>US</country><doc-number>5612205</doc-number><kind>A</kind><date>19970318</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653624" load-source="docdb" ucid="US-5631153-A"><document-id format="epo"><country>US</country><doc-number>5631153</doc-number><kind>A</kind><date>19970520</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653623" load-source="docdb" ucid="US-5633067-A"><document-id format="epo"><country>US</country><doc-number>5633067</doc-number><kind>A</kind><date>19970527</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653625" load-source="docdb" ucid="US-5646008-A"><document-id format="epo"><country>US</country><doc-number>5646008</doc-number><kind>A</kind><date>19970708</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653626" load-source="docdb" ucid="US-5851832-A"><document-id format="epo"><country>US</country><doc-number>5851832</doc-number><kind>A</kind><date>19981222</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653627" load-source="docdb" ucid="US-6200806-B1"><document-id format="epo"><country>US</country><doc-number>6200806</doc-number><kind>B1</kind><date>20010313</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653628" load-source="docdb" ucid="US-6235970-B1"><document-id format="epo"><country>US</country><doc-number>6235970</doc-number><kind>B1</kind><date>20010522</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653629" load-source="docdb" ucid="US-6280718-B1"><document-id format="epo"><country>US</country><doc-number>6280718</doc-number><kind>B1</kind><date>20010828</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377626103" load-source="docdb" ucid="US-65581500-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>65581500</doc-number><kind>A</kind><date>20000906</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377617014" load-source="docdb" ucid="US-65617300-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>65617300</doc-number><kind>A</kind><date>20000906</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377625283" load-source="docdb" ucid="US-68506100-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>68506100</doc-number><kind>A</kind><date>20001006</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377624119" load-source="docdb" ucid="US-69729700-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>69729700</doc-number><kind>A</kind><date>20001027</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377617890" load-source="docdb" ucid="US-73626800-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>73626800</doc-number><kind>A</kind><date>20001215</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377616651" load-source="docdb" ucid="US-79768401-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>79768401</doc-number><kind>A</kind><date>20010305</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377622122" load-source="docdb" ucid="US-80901801-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>80901801</doc-number><kind>A</kind><date>20010316</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377623210" load-source="docdb" ucid="US-87404001-A" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>87404001</doc-number><kind>A</kind><date>20010606</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653632" load-source="docdb" ucid="WO-1993022432-A1"><document-id format="epo"><country>WO</country><doc-number>1993022432</doc-number><kind>A1</kind><date>19931111</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653631" load-source="docdb" ucid="WO-2001030978-A1"><document-id format="epo"><country>WO</country><doc-number>2001030978</doc-number><kind>A1</kind><date>20010503</date></document-id><sources><source name="SEA" category="I" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242653630" load-source="docdb" ucid="WO-2001032015-A1"><document-id format="epo"><country>WO</country><doc-number>2001032015</doc-number><kind>A1</kind><date>20010510</date></document-id><sources><source name="SEA" category="I" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>ADAMS ET AL., SCIENCE, vol. 281, no. 5381, 1998, pages 1322 - 1326</text><sources><source mxw-id="PNPL56786480" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>ASSADY ET AL., DIABETES, vol. 50, no. 8, 2001, pages 1691 - 1697</text><sources><source mxw-id="PNPL56786481" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CHARLES A. JANEWAY ET AL.: "Immunobiology", 2001, GARLAND PUBLISHING, pages: 524</text><sources><source mxw-id="PNPL56786482" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CIBELLI ET AL., SCIENCE, vol. 295, 2002, pages 81</text><sources><source mxw-id="PNPL56786483" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CIBELLI JOSE B ET AL: "Parthenogenetic Stem Cells in Nonhuman Primates", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 295, no. 5556, 1 February 2002 (2002-02-01), pages 819, XP008091029, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1065637</text><sources><source mxw-id="PNPL56786484" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>CIBELLI, J.B. ET AL.: "Parthenogenetic stem calls in non-human primates", SCIENCE, vol. 295, 2002, pages 819</text><sources><source mxw-id="PNPL56786485" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>EVANS, NATURE, vol. 292, 1981, pages 154 - 156</text><sources><source mxw-id="PNPL56786486" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HAGEMMAN; FIRST, DEVELOPMENT, vol. 114, 1992, pages 997 - 1001</text><sources><source mxw-id="PNPL56786487" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>INVERARDI ET AL.: "Transplantation Biology, Cellular and Molecular Aspects", 1996, LIPPINCOTT-RAVEN</text><sources><source mxw-id="PNPL56786488" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KIM KITAI ET AL: "Histocompatible embryonic stem cells by parthenogenesis", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 315, no. 5811, 26 January 2007 (2007-01-26), pages 482 - 486, XP002467552, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1133542</text><sources><source mxw-id="PNPL56786489" load-source="docdb" name="SEA" category="T"/></sources></nplcit><nplcit><text>L. M. HOUDEBINE: "Transgenic Animals, Generation and Use", 1997, HARDWOOD ACADEMIC PUBLISHERS</text><sources><source mxw-id="PNPL56786490" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>LACHEM-KAPLAN ET AL., RB ONLINE, vol. 3, 2001, pages 205 - 211</text><sources><source mxw-id="PNPL56786491" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>LIN ET AL., STEM CELLS, vol. 21, 2003, pages 152 - 161</text><sources><source mxw-id="PNPL56786492" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MARTIN, PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 7634 - 7638</text><sources><source mxw-id="PNPL56786493" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MITALIPOV ET AL., BIOLOGY OF REPRODUCTION, vol. 65, 2001, pages 253 - 259</text><sources><source mxw-id="PNPL56786494" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MITALIPOV S M ET AL: "PARTHENOGENETIC ACTIVATION OF RHESUS MONKEY OOCYTES AND RECONSTRUCTED EMBRYOS", BIOLOGY OF REPRODUCTION, NEW YORK, NY [U.A.] : ACADEM. PRESS, US, vol. 65, no. 1, 1 July 2001 (2001-07-01), pages 253 - 259, XP001117868, ISSN: 0006-3363, DOI: 10.1095/BIOLREPROD65.1.253</text><sources><source mxw-id="PNPL56786495" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>NATURE BIOTECHNOLOGY, vol. 21, no. 3, March 2003 (2003-03-01)</text><sources><source mxw-id="PNPL56786496" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PAQUIN ET AL., PROC. NAT. ACAD. SCI., vol. 99, 2002, pages 9550 - 9555</text><sources><source mxw-id="PNPL56786497" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PROC. NATL. ACAD. SCI. USA., vol. 92, 1995, pages 7844 - 7848</text><sources><source mxw-id="PNPL56786498" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PROC. NATL. ACAD. SCI., USA, vol. 92, 1995, pages 7544 - 7848</text><sources><source mxw-id="PNPL56786499" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>REUBINOFF ET AL., NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 1134 - 1140</text><sources><source mxw-id="PNPL56786500" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAMBROOK; FRITSCH; MANIATIS: "Molecular Cloning, a Laboratory Manual, 2nd Ed.,", 1989, COLD SPRING HARBOR LABORATORY PRESS</text><sources><source mxw-id="PNPL56786501" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SCIENCE, vol. 282, 1988, pages 1145 - 1147</text><sources><source mxw-id="PNPL56786502" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SHOUKHRAT ET AL., BIOL REPROD, vol. 65, 2001, pages 253 - 259</text><sources><source mxw-id="PNPL56786503" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SZABO,PE; MANN, JR, GENES &amp; DEVELOPMENT, vol. 9, 1995, pages 3097 - 3108</text><sources><source mxw-id="PNPL56786504" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>TESARIK ET AL., RB ONLINE, vol. 2, 2001, pages 160 - 164</text><sources><source mxw-id="PNPL56786505" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>VAN DOORNINCK J H ET AL: "A MOUSE MODEL FOR THE CYSTIC FIBROSIS DELTA-F508", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 18, 1 January 1995 (1995-01-01), pages 4403 - 4411, XP008069832, ISSN: 0261-4189</text><sources><source mxw-id="PNPL56786506" load-source="docdb" name="SEA" category="I"/></sources></nplcit><nplcit><text>WAKAYAMA, T.; YANAGIMACHI, R., BIOL. REPROD., vol. 59, no. 1, 1998, pages 100 - 4</text><sources><source mxw-id="PNPL56786507" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>WEISS ET AL., HEMATOL. ONCOL. CLIN. N. AMER., vol. 11, no. 6, 1997, pages 1185 - 98</text><sources><source mxw-id="PNPL56786508" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>XU ET AL., NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 971 - 4</text><sources><source mxw-id="PNPL56786509" load-source="docdb" name="APP"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-13186524-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13186524</doc-number><kind>A</kind><date>20030527</date></document-id></child-doc><parent-doc ucid="EP-03736723.2"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>03736723.2</doc-number><date>20030527</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR918133290" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ADVANCED CELL TECH INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR918171310" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>ADVANCED CELL TECHNOLOGY, INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR918988093" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Advanced Cell Technology, Inc.</last-name><iid>100071672</iid><address><street>One Innovation Drive</street><city>Worcester, MA 01605</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918139714" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>WEST MICHAEL D</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918162912" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>WEST, MICHAEL D.</last-name></addressbook></inventor><inventor mxw-id="PPAR918987074" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>WEST, MICHAEL D.</last-name><address><street>One Innovation Drive</street><city>Worchester, MA 01605</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918985457" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Daniels, Jeffrey Nicholas</last-name><suffix>et al</suffix><iid>100033084</iid><address><street>Page White &amp; Farrer Bedford House John Street</street><city>London WC1N 2BF</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS548892248" load-source="docdb">AT</country><country mxw-id="DS548807407" load-source="docdb">BE</country><country mxw-id="DS548889824" load-source="docdb">BG</country><country mxw-id="DS548848752" load-source="docdb">CH</country><country mxw-id="DS548902747" load-source="docdb">CY</country><country mxw-id="DS548892249" load-source="docdb">CZ</country><country mxw-id="DS548807408" load-source="docdb">DE</country><country mxw-id="DS548902748" load-source="docdb">DK</country><country mxw-id="DS548902749" load-source="docdb">EE</country><country mxw-id="DS548897803" load-source="docdb">ES</country><country mxw-id="DS548889825" load-source="docdb">FI</country><country mxw-id="DS548889826" load-source="docdb">FR</country><country mxw-id="DS548807409" load-source="docdb">GB</country><country mxw-id="DS548902834" load-source="docdb">GR</country><country mxw-id="DS548892254" load-source="docdb">HU</country><country mxw-id="DS548848753" load-source="docdb">IE</country><country mxw-id="DS548889827" load-source="docdb">IT</country><country mxw-id="DS548902835" load-source="docdb">LI</country><country mxw-id="DS548892255" load-source="docdb">LU</country><country mxw-id="DS548885408" load-source="docdb">MC</country><country mxw-id="DS548897804" load-source="docdb">NL</country><country mxw-id="DS548848754" load-source="docdb">PT</country><country mxw-id="DS548897805" load-source="docdb">RO</country><country mxw-id="DS548812536" load-source="docdb">SE</country><country mxw-id="DS548848755" load-source="docdb">SI</country><country mxw-id="DS548889828" load-source="docdb">SK</country><country mxw-id="DS548902836" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128670490" lang="EN" load-source="patent-office"><p id="pa01" num="0001">Methods for producing stem cell banks, preferably human, which optionally may be transgenic, e.g., comprised of homozygous MHC allele cell lines are provided. These cells are produced preferably from parthenogenic, IVF, or same-species or cross-species nuclear transfer embryos or by de-differentiation of somatic cells by cytoplasm transfer. Methods for using these stem cell banks for producing stem and differentiated cells for therapy, especially acute therapies, and for screening for drugs for disease treatment are also provided.</p></abstract><abstract mxw-id="PA128499863" lang="EN" source="EPO" load-source="docdb"><p>Methods for producing stem cell banks, preferably human, which optionally may be transgenic, e.g., comprised of homozygous MHC allele cell lines are provided. These cells are produced preferably from parthenogenic, IVF, or same-species or cross-species nuclear transfer embryos or by de-differentiation of somatic cells by cytoplasm transfer. Methods for using these stem cell banks for producing stem and differentiated cells for therapy, especially acute therapies, and for screening for drugs for disease treatment are also provided.</p></abstract><description mxw-id="PDES63955920" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">FIELD OF THE INVENTION</heading><p id="p0001" num="0001">The invention described herein relates to methods for producing a collection of human and non-human stem cell cultures, preferably human stem cell cultures, each of which contains totipotent or pluripotent stem cells that have genes encoding the same set of critical cell surface antigenic proteins, e.g., histocompatibility antigens(e.g., HLA antigens in the case of human) as are present on the cells of members of a human population. (By critical antigens is meant the set of antigens that form the major histocompatibility complex and other antigens such as blood group antigens that are involved in immuno-mediated rejection when collogenic cells and tissues are transplanted into donors that express a different set of histocompatibility and other critical antigens). The methods disclosed herein include deriving such human stem cell cultures from cells of early embryos produced e.g. by in vitro fertilization, parthenogenesis, and by nuclear transfer. Also, stem cells can be produced by transfer of cytoplasm from embryonic cells, e.g. oocytes, early embryonic cells or ES cells into somatic cells.<br/>
<!-- EPO <DP n="2"> -->The invention described herein also relates to methods wherein such human and non-human stem cell cultures are induced to differentiate ex or in vivo into cell types that are useful for therapeutic cell transplantation; and to methods by which the differentiated cells are isolated from other cell types. The invention also relates to methods in which stem cell-derived differentiated cells having a selected set of critical cell surface antigens are therapeutically transplanted or engrafted to a recipient, e.g., a human patient in need of a cell transplant having cells that express the same critical cell surface antigens. The invention further relates to a collection or "bank" of cultures of different types of stem cells, each culture having a different set of genes encoding cell surface antigenic proteins present in a human population; to compositions comprising the individual stem cell cultures that make up such a stem cell bank; and to compositions comprising differentiated cells derived from such stem cells.<br/>
Preferably, stem cell banks produced according to the invention will comprise stem cell lines which are homozygous for MHC alleles which occur very frequently in the human population. Typically, a stem cell bank according to the invention will comprise at least 15 stem cell lines and more preferably at least 100 to 1000 stem cell lines. Thereby, the stem cell bank will provide maximal therapeutic and diagnostic efficacy as it will contain cells that are histocompatible for a wide range of potential transplant recipients.</p><heading id="h0002">BACKGROUND OF THE INVENTION</heading><heading id="h0003">A. <u>Histocompatibility and Transplant Rejection:</u></heading><p id="p0002" num="0002">Histocompatibility is a largely unsolved problem in transplant medicine. Rejection of transplanted tissue is the result of an adaptive immune response to alloantigens on the grafted tissue by the transplant recipient. The alloantigens are "non-self" proteins, i.e., antigenic proteins that vary among individuals in the population and are identified as foreign by the immune system of a transplant recipient. The antigens on the surfaces of transplanted<!-- EPO <DP n="3"> --> tissue that most strongly evoke rejection are the blood group (ABO) antigens and the major histocompatibity complex (MHC) proteins and in the case of humans, the human leukocyte antigen (HLA) proteins.</p><p id="p0003" num="0003">The blood group antigens were first described by Landsteiner in 1900; they are branched oligosaccharides that are attached to proteins and lipids on the surfaces of red blood cells, endothelial cells, and other cells, and are also present in secretions such as saliva. Compatibility of the blood group antigens of the ABO system of a vascularized organ or tissue transplant with those of the transplant recipient is generally required; but blood group compatibility may be unnecessary for many types of cell transplants.</p><p id="p0004" num="0004">The HLA proteins are encoded by clusters of genes that form a region located on chromosome 6 known as the Major Histocompatibility Complex, or MHC, in recognition of the important role of the proteins encoded by the MHC loci in graft rejection. Accordingly, the HLA proteins are also referred to as MHC proteins. The MHC genes and proteins will be used interchangeably in this application as the application encompasses human and non-human animal applications. The HLA or MHC proteins normally play a role in defending the body against foreign pathogens such as viruses, bacteria, and toxins. They are cell surface glycoproteins that bind peptides at intracellular locations and deliver them to the cell surface, where the combined ligand is recognized by a T cell. Class I MHC proteins are found on virtually all of the nucleated cells of the body. The class I MHC proteins bind peptides present in the cytosol and form peptide-MHC protein complexes that are presented at the cell surface, where they are recognized by cytotoxic CD8+ T cells. Class II MHC proteins are usually found only on antigen-presenting cells such as B lymphocytes, macrophages, and dendritic cells. The class II MHC proteins bind peptides present in a cell's vesicular system and form peptide-MHC protein complexes that are presented at the cell surface, where they are recognized by CD4+ T cells. CD4+ T cells activated by class II MHC proteins undergo clonal expansion with production of regulatory cytokines that signal helper and cytotoxic T cells. Unfortunately for<!-- EPO <DP n="4"> --> those in need of transplants, the frequency of T cells in the body that are specific for non-self MHC molecules is relatively high, with the result that differences at MHC loci are the most potent critical elicitors of rejection of initial grafts. Rejection of most transplanted tissues is triggered predominantly by the recognition of class I MHC proteins as non-self proteins. T cell recognition of foreign antigens on the transplanted tissue sets in motion a chain of signaling and regulatory events that causes the activation and recruitment of additional T cells and other cytotoxic cells, and culminates in the destruction of the transplanted tissue. (<nplcit id="ncit0001" npl-type="b"><text>Charles A. Janeway et al., Immunobiology, Garland Publishing, New York, NY, 2001, p. 524</text></nplcit>).</p><heading id="h0004">B. <u>The Genes Encoding MHC Proteins:</u></heading><p id="p0005" num="0005">The MHC genes are polygenic - each individual possesses multiple, different MHC class I and MHC class II genes. The MHC genes are also polymorphic - many variants of each gene are present in the human and non-human population. In fact, the MHC genes are the most polymorphic genes known. Each MHC Class I receptor consists of a variable <i>α</i> chain and a relatively conserved <i>β</i>2-microglobulin chain. Three different, highly polymorphic class I <i>α</i> chain genes have been identified. These are called HLA-A, HLA-B, and HLA-C. Variations in the <i>α</i> chain chains account for all of the different class I MHC genes in the population. MHC Class II receptors are also made up of two polypeptide chains, an <i>α</i> chain and a <i>β</i> chain, both of which are polymorphic. In humans, there are three pairs of MHC class II <i>α</i> and <i>β</i> chain genes, called HLA-DR, HLA-DP, and HLA-DQ. Frequently, the HLA-DR cluster contains an extra gene encoding a <i>β</i> chain that can combine with the DR <i>α</i> chain; thus, an individual's three MHC Class II genes can give rise to four different MHC Class II molecules.</p><p id="p0006" num="0006">In humans, the genes encoding the MHC class I <i>α</i> chains and the MHC class II a and <i>β</i> chain are clustered on the short arm of chromosome 6 in a region that extends over from 4 to 7 million base pairs that is called the major histocompatibility complex. Every person usually inherits a copy of<!-- EPO <DP n="5"> --> each HLA gene from each parent. If an individual's two alleles for a particular MHC locus encode structurally different proteins, the individual is heterozygous for that MHC allele. If an individual has two MHC alleles that encode the same MHC molecule, the individual is homozygous for that MHC allele. Because there are so many different variants of the MHC alleles in the population, most people have heterozygous MHC alleles. The numbers of different alleles found for each type of MHC class I <i>α</i> chain and MHC class II <i>α</i> and <i>β</i> chains as of January 2003 are shown in Table 1.</p><p id="p0007" num="0007"><tables id="tabl0001" num="0001"><table frame="all"><title>TABLE 1. The numbers of different alleles for the polymorphic MHC class I and class II chains identified as of January, 2003.</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="83mm"/><colspec colnum="2" colname="col2" colwidth="83mm"/><thead><row><entry align="center" valign="top">MHC chain</entry><entry align="center" valign="top">no. of alleles</entry></row></thead><tbody><row><entry align="center">HLA-A</entry><entry align="center">266</entry></row><row><entry align="center">HLA-B</entry><entry align="center">511</entry></row><row><entry align="center">HLA-C</entry><entry align="center">6</entry></row><row><entry align="center">HLA-DRA</entry><entry align="center">3</entry></row><row><entry align="center">HLA-DRB</entry><entry align="center">403</entry></row><row><entry align="center">HLA-DQA1</entry><entry align="center">23</entry></row><row><entry align="center">HLA-DQB1</entry><entry align="center">53</entry></row><row><entry align="center">HLA-DPA1</entry><entry align="center">20</entry></row><row><entry align="center">HLA-DPB1</entry><entry align="center">101</entry></row></tbody></tgroup></table></tables></p><p id="p0008" num="0008">The data in Table 1 is from the Internet web site of the Informatics Group of the Anthony Nolan Trust, The Royal Free Hospital, Hampstead, London, England. Lists of identified HLA Class I and Class II alleles are also available at the same web site.</p><heading id="h0005">C. <u>Matching MHC Types to Inhibit Rejection of Transplants:</u></heading><p id="p0009" num="0009">Since the recognition that non-self MHC molecules are a major determinant of graft rejection, much effort has been put into developing<!-- EPO <DP n="6"> --> assays to identify the MHC types present on the cells of tissue to be transplanted, and on the cells of transplant recipients, in order to match the types of MHC molecules present in the transplant tissue with those of the recipient. Tissue typing, the detection of MHC antigens, is performed by various means; for example, (i) by serology, using antibodies specific for particular MHC molecules to detect the presence of the targeted MHC molecules on donor or recipient cells, e.g., by the lymphocytotoxicity test; (ii) by detection of antibodies of a transplant recipient that bind specifically to a MHC protein of transplant tissue; and (iii) by direct analysis of the nucleotide sequence of the DNA of the MHC alleles. Most tissue typing for organ banking purposes is done by determining the blood type (ABO typing) and by typing the patient's and donor cells using serological methods; however, the use of rapid and reliable DNA-specific methods is increasing. Such methods can employ sequence-specific oligonucleotide primers and amplification by the polymerase chain reaction (PCR), and can be augmented by combining fluorescent detection methods with the use of a DNA chip to which are bound sequence specific oligonucleotides designed to detect unique sequences present in the different MHC alleles.</p><p id="p0010" num="0010">At present, tissue typing to match the HLA antigens of a transplant with those of a recipient is usually limited to the Class I HLA-A and -B antigens, and the Class II HLA-DR antigens. Most transplant donors are unrelated to the transplant recipient, and finding a tissue type to match that of the recipient usually involves matching the blood type and as many as possible of the 6 HLA alleles - two for each HLA-A, -B, and -DR locus. Transplant centers do not usually consider potential incompatibilites at other HLA loci, such as HLA-C and HLA-DPB1, although mismatches at these loci can also contribute to rejection. Considering only the combinations of maternal and paternal alleles of the HLA-A, HLA-B, and HLA-DR loci identified to date, there is a complexity of billions of possible tissue types. The task of matching HLA types of organs for transplant is simplified in that HLA-A and HLA-B are usually identified serologically. The number of HLA<!-- EPO <DP n="7"> --> antigens identified serologically is considerably less than the number of different HLA antigens based on DNA sequencing. The World Health Organization (WHO) has recognized 28 distinct antigens in the HLA-A locus and 59 in the HLA-B locus, based on serological typing. Matching organs is also simplified to some extent by the fact that some alleles are much more common than others. Some of the more common HLA-A and HLA-B alleles are shown in Table 2:</p><p id="p0011" num="0011"><tables id="tabl0002" num="0002"><table frame="none"><title>Table 2. Frequency of common HLA-A and HLA-B alleles in the population.</title><tgroup cols="2" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="53mm"/><colspec colnum="2" colname="col2" colwidth="53mm"/><thead><row><entry valign="top">HLA-A (Frequency (%))</entry><entry valign="top">HLA-B (Frequency (%))</entry></row></thead><tbody><row><entry>HLA-A1 (25.1)</entry><entry>HLA-B5 (15.2)</entry></row><row><entry>HLA-A2 (44.8)</entry><entry>HLA-B7 (18.2)</entry></row><row><entry>HLA-A3 (22.6)</entry><entry>HLA-B8 (16.7)</entry></row><row><entry>HLA-A24 (18.2)</entry><entry>HLA-B12 (32.5)</entry></row><row><entry>HLA-A11 (11.8)</entry><entry>HLA-B14 (8.8)</entry></row><row><entry>HLA-A28 (9.8)</entry><entry>HLA-B18 (11.3)</entry></row><row><entry>HLA-A29 (10.3)</entry><entry>HLA-B35 (15.2)</entry></row><row><entry>HLA-A32 (9.8)</entry><entry>HLA-B40 (13.7)</entry></row><row><entry>HLA-B15 (12.3)</entry><entry/></row></tbody></tgroup></table></tables>
(from <nplcit id="ncit0002" npl-type="b"><text>Snell GD et al, Histocompatibility, New York, Academic Press, 1976</text></nplcit>)</p><p id="p0012" num="0012">The frequencies with which the various alleles appear in a population is not random; it depends on the racial makeup of the population. Dr. Motomi Mori has determined the frequencies with which thousand of different haplotypes of HLA-A, -B, and -DR loci appear in Caucasian, African-American, Asian-American, and Native American populations. Each haplotype is a particular combination of HLA-A, HLA-B, and HLA-DR loci that is present on a single copy of chromosome no. 6. The frequencies of several relatively common HLA-A, -B, and -DR haplotypes are shown in Table 3 to illustrate the wide variation in HLA haplotype frequencies in some of the racial groups that make up the North American population. In interpreting haplotype frequency data such as that shown in Table 3, one must bear in mind that<!-- EPO <DP n="8"> --> cells of patients and organs are diploid and have an HLA type that is the product of the HLA haplotypes of the chromosomes inherited from both parents.
<tables id="tabl0003" num="0003"><table frame="none"><title>Table 3. Examples of HLA-A, -B, -DR haplotype frequencies HLA-A, -B, and -DR haplotype frequencies (expressed in percent) and their respective rankings within each racial group: Caucasian (CAU), African-American (AFR), Asian-American (ASI) and Native American (NAT).</title><tgroup cols="13" colsep="0"><colspec colnum="1" colname="col1" colwidth="11mm"/><colspec colnum="2" colname="col2" colwidth="11mm"/><colspec colnum="3" colname="col3" colwidth="11mm"/><colspec colnum="4" colname="col4" colwidth="15mm"/><colspec colnum="5" colname="col5" colwidth="15mm"/><colspec colnum="6" colname="col6" colwidth="15mm"/><colspec colnum="7" colname="col7" colwidth="15mm"/><colspec colnum="8" colname="col8" colwidth="15mm"/><colspec colnum="9" colname="col9" colwidth="12mm"/><colspec colnum="10" colname="col10" colwidth="12mm"/><colspec colnum="11" colname="col11" colwidth="15mm"/><colspec colnum="12" colname="col12" colwidth="12mm"/><colspec colnum="13" colname="col13" colwidth="12mm"/><thead><row><entry namest="col1" nameend="col3" align="center" valign="top">Haplotype</entry><entry namest="col4" nameend="col8" align="center" valign="top">Frequency (%)</entry><entry namest="col9" nameend="col13" align="center" valign="top">Ranking</entry></row><row><entry align="center" valign="top">A</entry><entry align="center" valign="top">B</entry><entry align="center" valign="top">DR</entry><entry align="center" valign="top">CAU</entry><entry align="center" valign="top">AFR</entry><entry align="center" valign="top">ASI</entry><entry align="center" valign="top">LAT</entry><entry align="center" valign="top">NAT</entry><entry align="center" valign="top">CAU</entry><entry align="center" valign="top">AFR</entry><entry align="center" valign="top">ASI</entry><entry align="center" valign="top">LAT</entry><entry align="center" valign="top">NAT</entry></row></thead><tbody><row><entry align="center">1</entry><entry align="center">7</entry><entry align="center">2</entry><entry align="char" char=".">0.5349</entry><entry align="char" char="." charoff="12">0.2094</entry><entry align="char" char="." charoff="12">0.0798</entry><entry align="char" char="." charoff="12">0.1888</entry><entry align="char" char="." charoff="12">0.2812</entry><entry align="center">21</entry><entry align="center">58</entry><entry align="center">262</entry><entry align="center">91</entry><entry align="center">62</entry></row><row><entry align="center">1</entry><entry align="center">8</entry><entry align="center">3</entry><entry align="char" char=".">5.1812</entry><entry align="char" char="." charoff="12">1.2491</entry><entry align="char" char="." charoff="12">0.3195</entry><entry align="char" char="." charoff="12">1.6733</entry><entry align="char" char="." charoff="12">4.7439</entry><entry align="center">1</entry><entry align="center">2</entry><entry align="center">54</entry><entry align="center">3</entry><entry align="center">1</entry></row><row><entry align="center">2</entry><entry align="center">14</entry><entry align="center">1</entry><entry align="char" char=".">0.1563</entry><entry align="char" char="." charoff="12">0.0444</entry><entry align="char" char="." charoff="12">0.0076</entry><entry align="char" char="." charoff="12">0.3794</entry><entry align="char" char="." charoff="12">0.0624</entry><entry align="center">107</entry><entry align="center">539</entry><entry align="center">1451</entry><entry align="center">39</entry><entry align="center">312</entry></row><row><entry align="center">2</entry><entry align="center">35</entry><entry align="center">4</entry><entry align="char" char=".">0.1457</entry><entry align="char" char="." charoff="12">0.0737</entry><entry align="char" char="." charoff="12">0.3293</entry><entry align="char" char="." charoff="12">1.2858</entry><entry align="char" char="." charoff="12">0.6342</entry><entry align="center">115</entry><entry align="center">302</entry><entry align="center">49</entry><entry align="center">4</entry><entry align="center">12</entry></row><row><entry align="center">2</entry><entry align="center">35</entry><entry align="center">8</entry><entry align="char" char=".">0.0823</entry><entry align="char" char="." charoff="12">0.0931</entry><entry align="char" char="." charoff="12">0.1756</entry><entry align="char" char="." charoff="12">1.7641</entry><entry align="char" char="." charoff="12">0.3289</entry><entry align="center">241</entry><entry align="center">226</entry><entry align="center">122</entry><entry align="center">1</entry><entry align="center">46</entry></row><row><entry align="center">2</entry><entry align="center">44</entry><entry align="center">4</entry><entry align="char" char=".">2.1507</entry><entry align="char" char="." charoff="12">0.6506</entry><entry align="char" char="." charoff="12">0.1276</entry><entry align="char" char="." charoff="12">0.6906</entry><entry align="char" char="." charoff="12">2.0004</entry><entry align="center">3</entry><entry align="center">4</entry><entry align="center">170</entry><entry align="center">12</entry><entry align="center">3</entry></row><row><entry align="center">3</entry><entry align="center">7</entry><entry align="center">2</entry><entry align="char" char=".">2.6285</entry><entry align="char" char="." charoff="12">0.7596</entry><entry align="char" char="." charoff="12">0.1891</entry><entry align="char" char="." charoff="12">1.1986</entry><entry align="char" char="." charoff="12">2.7083</entry><entry align="center">2</entry><entry align="center">3</entry><entry align="center">113</entry><entry align="center">5</entry><entry align="center">2</entry></row><row><entry align="center">3</entry><entry align="center">7</entry><entry align="center">4</entry><entry align="char" char=".">0.4411</entry><entry align="char" char="." charoff="12">0.1534</entry><entry align="char" char="." charoff="12">0.0498</entry><entry align="char" char="." charoff="12">0.1795</entry><entry align="char" char="." charoff="12">0.4448</entry><entry align="center">30</entry><entry align="center">104</entry><entry align="center">408</entry><entry align="center">98</entry><entry align="center">29</entry></row><row><entry align="center">3</entry><entry align="center">7</entry><entry align="center">8</entry><entry align="char" char=".">0.0848</entry><entry align="char" char="." charoff="12">0.0367</entry><entry align="char" char="." charoff="12">0.0000</entry><entry align="char" char="." charoff="12">0.0622</entry><entry align="char" char="." charoff="12">0.0537</entry><entry align="center">230</entry><entry align="center">653</entry><entry align="center">14053</entry><entry align="center">310</entry><entry align="center">366</entry></row><row><entry align="center">3</entry><entry align="center">35</entry><entry align="center">1</entry><entry align="char" char=".">1.0224</entry><entry align="char" char="." charoff="12">0.2741</entry><entry align="char" char="." charoff="12">0.1372</entry><entry align="char" char="." charoff="12">0.3552</entry><entry align="char" char="." charoff="12">0.8125</entry><entry align="center">7</entry><entry align="center">29</entry><entry align="center">156</entry><entry align="center">44</entry><entry align="center">8</entry></row><row><entry align="center">31</entry><entry align="center">51</entry><entry align="center">4</entry><entry align="char" char=".">0.0915</entry><entry align="char" char="." charoff="12">0.0342</entry><entry align="char" char="." charoff="12">0.1646</entry><entry align="char" char="." charoff="12">0.2597</entry><entry align="char" char="." charoff="12">0.5691</entry><entry align="center">209</entry><entry align="center">699</entry><entry align="center">135</entry><entry align="center">64</entry><entry align="center">16</entry></row><row><entry align="center">32</entry><entry align="center">14</entry><entry align="center">7</entry><entry align="char" char=".">0.2617</entry><entry align="char" char="." charoff="12">0.0513</entry><entry align="char" char="." charoff="12">0.0046</entry><entry align="char" char="." charoff="12">0.1324</entry><entry align="char" char="." charoff="12">0.1775</entry><entry align="center">57</entry><entry align="center">479</entry><entry align="center">1858</entry><entry align="center">140</entry><entry align="center">104</entry></row></tbody></tgroup></table></tables>
The data in Table 3 was produced for The National Marrow Donor Program Donor Registry, and is available at the Internet web site of Motomi Mori, Ph.D., Huntsman Cancer Institute, Salt Lake City, Utah.<!-- EPO <DP n="9"> --></p><heading id="h0006">D. <u>Reiection Triggered by Minor Histocompatibility Antigens:</u></heading><p id="p0013" num="0013">Matching the MHC molecules of a transplant to those of the recipient significantly improves the success rate of clinical transplantation; however, it does not prevent rejection, even when the transplant is between HLA-identical siblings. This is because rejection is also triggered by differences between the minor histocompatibility antigens. These polymorphic antigens are actually "non-self" peptides bound to MHC molecules on the cells of the transplant tissue. The rejection response evoked by a single minor histocompatibility antigen is much weaker than that evoked by differences in MHC antigens, because the frequency of the responding T cells is much lower (Janeway et al., supra, page 525). Nonetheless, differences between minor histocompatibility antigens will often cause the immune system of a transplant recipient to eventually reject a transplant, even where there is a match between the MHC antigens, unless immunosuppressive drugs are used.</p><heading id="h0007">E. <u>Inadequate Supply of Cells, Tissues, and Organs for Transplant.</u></heading><p id="p0014" num="0014">The number of people in need of cell, tissue, and organ transplants is far greater than the available supply of cells, tissues, and organs suitable for transplantation. Under these circumstances, it is not surprising that obtaining a good match between the MHC proteins of a recipient and those of the transplant is frequently impossible, and many transplant recipients must wait for an MHC-matched transplant to become available, or accept a transplant that is not MHC-matched. If the latter is necessary, the transplant recipient must rely on heavier doses of immunosuppressive drugs and face a greater risk of rejection than would be the case if MHC matching had been possible. There is presently a great need for new sources of cells, tissues, and organs suitable for transplantation that are histocompatible with the patients in need of such transplants.<!-- EPO <DP n="10"> --></p><heading id="h0008"><u>BRIEF DESCRIPTION OF THE FIGURES</u></heading><p id="p0015" num="0015"><ul><li><figref idrefs="f0001">Figure 1</figref> shows cynomulgous monkey blastocysts derived from parthenogenetic embryos.</li><li><figref idrefs="f0002">Figure 2</figref> shows an ES-like cell line (Cyno 1) derived from a cynomulgous parthenogenetic blastocyst.</li><li><figref idrefs="f0003">Figure 3</figref> and <figref idrefs="f0004">4</figref> show the Cyno 1 cell line before and after immunosurgery.</li><li><figref idrefs="f0005">Figure 5</figref> shows the Cyno 1 cell line 5 days after plating.</li><li><figref idrefs="f0006">Figure 6</figref> shows the Cyno 1 cell line growing on top of a feeder layer.</li><li><figref idrefs="f0007">Figure 7</figref> shows the results of an RT-PCR showing that the Cyno-1 cell line is homozygous for the Snrpn gene (contains paternal allele).</li><li><figref idrefs="f0008">Figure 8</figref> shows metaphase II oocytes at retrieval.</li><li><figref idrefs="f0009">Figure 9</figref> shows 4 and 6 cell embryo 48 hours after parthenogenetic activation.</li><li><figref idrefs="f0010">Figure 10</figref> shows blastocoele cavities in human parthenogenetic activation 48 hours after activation.</li><li><figref idrefs="f0011">Figure 11</figref> shows human parthenogenetic embryo having an inner cell mass.</li><li><figref idrefs="f0012">Figure 12</figref> shows human ES-like cells derived from cultured ICM cells.</li></ul></p><heading id="h0009">DESCRIPTION OF THE INVENTION</heading><heading id="h0010">A. <u>A Bank Of Stem Cell Lines Homozygous For MHC Loci:</u></heading><p id="p0016" num="0016">It is an object of the present invention to prepare a bank of totipotent, nearly totipotent, and/or pluripotent stem cell lines that are homozygous for one or more critical antigen genes, i.e., genes which encode histocompatibility antigens, e.g., in the case of human stem cells and "stem-like" cells, MHC alleles that are present in the human population. Preferably, this work will be homozygous for MHC alleles that are representative of at least most prevalent in the particular species, preferably human. Many of these lines will also have an ABO blood group type O-negative to make them broadly compatible across the different blood types. Stem cell lines of the<!-- EPO <DP n="11"> --> present invention can be induced to differentiate into cell types suitable for therapeutic transplant. Because the cells of the present invention have homozygous MHC alleles, the chance of obtaining cells for transplant that have MHC alleles that match those of a patient in need of a transplant is significantly enhanced. Instead of having to find a six of six match between two sets of HLA-A, HLA-B, and HLA-DR antigens, a high level of histocompatibility is provided by the cells for transplant of the present invention when either of the two HLA-A, HLA-B, and HLA-DR antigens of the prospective transplant recipient matches one of the corresponding homozygous HLA antigens of the cells for transplant. For example, a stem cell bank able to provide cells having an HLA-A/HLA-B match to a patient having any of the eight HLA-A and nine HLA-B antigens listed in Table 2 would require only 72 stem cell lines with homozygous HLA-A and HLA-B antigens; whereas a bank of stem cells with heterozygous HLA-A and HLA-B antigens would need to have 4032 different stem cell lines. To provide a library of heterozygous stem cell lines that match the WHO list of serological types would require obtaining stem cells having every combination of 28 different pairs of HLA-A antigens and 59 different pairs of HLA-B, to account for both the maternal and paternal alleles for each loci. The complexity of such a stem cell bank, i.e., the number of different cell lines required, would be 2,587,032. In contrast, a bank of stem cells homozygous for the same HLA-A and HLA-B antigens would only need to have a complexity of 1,652 stem cell lines to guarantee a match to a patient with HLA-A and -B antigens on the WHO list of serological types. The actual number required to meet the needs of a majority of patients will actually be less than this due to the non-random distribution of alleles in various populations around the world. Patients in need of bone marrow stem cell grafts who are homozygous in particular alleles are particularly sensitive to graft versus host disease when heterozygous bone marrow grafts are used. Stem cell grafts using stem cells having homozygous alleles made according to the methods of the present invention would alleviate this common complication of transplants.<!-- EPO <DP n="12"> --> This present invention provides novel means for making libraries of totipotent and/or pluripotent stem cells that can serve as sources of cells for therapeutic transplant that are highly histocompatible with human or non-human patients in need of cell transplants. Additionally, those cell lines are useful in creating animal models for specific diseases that may be used to evaluate potential treatments and drug antidotes. In one embodiment, the invention comprises preparing a bank of stem cell lines that are homozygous for one or more critical antigen alleles, in the case of human stem cells. MHC alleles that are present in all or most of the world's populations, including the populations of North America, Central and South America, Europe, Africa, and Asia, and the Pacific islands. It is an object of the present invention to provide a stem cell bank comprising stem cells generated from vertebrate somatic cells, preferably mammalian somatic cells, and more preferably human research cells that are homozygous for one or more critical antigen alleles, e.g., MHC alleles using nuclear transfer or parthenogenic produced embryos. A preferred object of the present invention is to provide a stem cell bank comprising diploid vertebrate, preferably mammalian and more preferably human stem cells generated by parthenogenesis that are homozygous for MHC alleles. Another object of the present invention is to provide a stem cell bank comprising diploid vertebrate, preferably mammalian and more preferably human stem cells generated by union of sperm and egg in vitro that are homozygous for one or more MHC alleles. S&amp;M further, an object of the invention is to preview a bank of homozygous IES cell lines by introducing cytoplasm from embryonic cells into growth cells that are homozygous for specific MITC allele or are rendered homozygous by genetic manipulation. (The embryonic cytoplasm contains constituents that de-differentiate the differentiated growth cell into stem cell lineages.</p><p id="p0017" num="0017">The stem cell bank of the present invention comprises lines of totipotent, nearly totipotent, and/or pluripotent stem cells that are homozygous for at least one histocompatibility antigen collection. In the case of human stem cells this will be an MHC allele selected from the group consisting of<!-- EPO <DP n="13"> --> HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP. In a useful embodiment, the stem cell bank comprises totipotent, nearly totipotent, and/or pluripotent stem cells stem cells that are homozygous for the significant histocompatibility antigen alleles, e.g., the HLA-A, HLA-B, and HLA-DR alleles. In another embodiment, the stem cell bank comprises stem cells that are homozygous for all of the histocompatibility antigen alleles, e.g., MHC alleles.</p><p id="p0018" num="0018">The stem cell bank of the present invention comprises totipotent and/or nearly totipotent stem cells such as embryonic stem (ES) cells, that can differentiate in vivo or ex vivo into a wide variety of different cell types having one or more homozygous MHC alleles. The stem cell bank of the present invention can also comprise partially differentiated, pluripotent stem cells such as neuronal stem cells and/or hematopoietic stem cells, that differentiate in vivo or ex vivo into a more limited number of differentiated cell types having one or more homozygous MHC alleles. These stem cells optionally may be transgenic, e.g., they may express antigens that encode therapeutic or diagnostic proteins and polypeptides. For example, the stem cells may be genetically engineered to express proteins that inhibit immune rejection responses such as CD4O-L (CD154 or gp139) or in the case of porcine stem cells may be genetically engineered to knock-out a glycosylated antigen that is known to trigger immune rejection responses.</p><p id="p0019" num="0019">An object of the present invention is to provide a stem cell bank comprising stem cells having homozygous histocompatibility alleles, i.e., MHC alleles that are available "off the shelf" for providing histocompatible cells suitable for transplant to patients in need of such a transplant. Desirably, this stem bank will include stem cell lines that are representative of the different histocompatibility antigens expressed in the particular species, e.g., human. In a useful embodiment, the stem cell bank comprises stem cells that are isolated and maintained without feeder cells or serum of non-human animals, to minimize concerns of contamination by pathogens. In another useful embodiment, the stem cell bank comprises stem cells that are genetically<!-- EPO <DP n="14"> --> modified relative to the cells of the donor, e.g., human donor from which they are derived. In another embodiment, the stem cell bank comprises stem cells generated by nuclear transfer techniques that are rejuvenated, or "hyper-youthful," relative to the cells of the donor, e.g., non-human mammal or human donor from which they are derived, and also relative to age-matched control cells of the same type and species that are not generated by nuclear transfer techniques. Such rejuvenated or "hyper-youthful" cells have extended telomeres, increased proliferative life-span, and metabolism that is more characteristic of youthful cells, e.g., increased EPC-1 and telomerase activities, relative to the human donor cells from which they are derived, and also relative to age-matched control cells of the same type that are not generated by nuclear transfer techniques.</p><p id="p0020" num="0020">Another object of the present invention is to provide a stem cell bank comprising stem cells having homozygous recessive alleles responsible for genetically inherited diseases. Recessive disease-causing genes are endemic in the population, and such stem cells can be generated by parthenogenesis using oocytes collected from female carriers of the recessive disease-causing alleles. There is great need for totipotent, nearly totipotent, and/or pluripotent stem cells that having homozygous recessive disease-causing alleles that can be induced to differentiate into cells useful for basic research directed to studying the disease phenotype, both ex vivo and in vivo (e.g., in immunodeficient laboratory animals), and for screening to discover drugs and other therapies that treat or cure the disease.</p><heading id="h0011">B. <u>Terms Used in Describing the Invention:</u></heading><p id="p0021" num="0021">As used herein, a "stem cell" is a cell that has the ability to proliferate in culture, producing some daughter cells that remain relatively undifferentiated, and other daughter cells that give rise to cells of one or more specialized cell types; and "differentiation" refers to a progressive, transforming process whereby a cell acquires the biochemical and morphological properties necessary to perform its<!-- EPO <DP n="15"> --> specialized functions. Stem cells therefore reside immediately antecedent to the branch points of the developmental tree.</p><p id="p0022" num="0022">As used herein, a "totipotent" cell is a stem cell with the "total power" to differentiate into any cell type in the body, including the germ line following exposure to stimuli like that normally occurring in development. Examples of totipotent cells include an embryonic stem (ES) cell, an embryonic germ (EG) cell, an inner cell mass (ICM)-derived cell, or a cultured cell from the epiblast of a late-stage blastocyst.</p><p id="p0023" num="0023">As used herein, a "nearly totipotent cell" is a stem cell with the power to differentiate into most or nearly all of the cell types in the body following exposure to stimuli like that normally occurring in development.</p><p id="p0024" num="0024">As used herein, a "pluripotent cell" is a stem cell that is capable of differentiating into multiple somatic cell types, but not into most or all cell types. This would include by way of example, but not limited to, mesenchymal stem cells that can differentiate into bone, cartilage and muscle; hematopoietic stem cells that can differentiate into blood, endothelium, and myocardium; neuronal stem cells that can differentiate into neurons and glia; and so on.</p><p id="p0025" num="0025">As used herein, an "embryonic stem cell line" is a cell line with the characteristics of the murine ES cells isolated from morulae or blastocyst inner cell masses, as reported by <nplcit id="ncit0003" npl-type="s"><text>Martin (Proc. Natl. Acad. Sci. USA (1981) 78:7634-7638</text></nplcit>); and by <nplcit id="ncit0004" npl-type="s"><text>Evans et al. (Nature (1981) 292:154-156</text></nplcit>). ES cells have high nuclear-to-cytoplasm ratio, prominent nucleoli, are capable of proliferating indefinitely and can be differentiate into most or all of the specialized cell types of an organism, such as the three embryonic germ layers, all somatic cell lineages, and the germ line. ES cells that can differentiate into all of the specialized cell types of an organism are totipotent. In some cases, ES cells are obtained that can differentiate into almost all of the specialized cell types of an organism; but not into one or a small number of specific cell types. For example, Thomson et al. describe isolating a primate ES cell that, when transferred into another blastocyst, does not contribute to the germ line (<nplcit id="ncit0005" npl-type="s"><text>Proc. Natl. Acad. Sci. USA. (1995) 92:7844-7848</text></nplcit>). Such ES cells are an example of stem cells that are nearly totipotent.<!-- EPO <DP n="16"> --></p><p id="p0026" num="0026">As used herein, "inner cell mass-derived cells" (ICM-derived cells) are cells directly derived from isolated ICMs or morulae without passaging them to establish a continuous ES or ES-like cell line. Methods for making and using ICM-derived cells are described in co-owned <patcit id="pcit0001" dnum="US6235970B"><text>U.S. Patent No. 6,235,970</text></patcit>, the contents of which are incorporated herein in their entirety.</p><p id="p0027" num="0027">As used herein, "enucleation" refers to removal of the genomic DNA from an cell, e.g., from a recipient oocyte. Enucleation therefore includes removal of genomic DNA that is not surrounded by a nuclear membrane, e.g., removal of chromosomes alligned to form a metaphase plate. As discussed below, the recipient cell can be enucleated by any of the known means either before, concomitant with, or after nuclear transfer.</p><p id="p0028" num="0028">As used herein, "ex vivo" cell culture refers to culturing cells outside of the body. Ex vivo cell culture includes cell culture in vitro, e.g., in suspension, or in single- or multi-well plates. Ex vivo culture also includes co-culturing cells with two or more different cell types, and culturing in or on 2- or 3-dimensional supports or matrices, including methods for culturing cells alone or with other cell types to form artificial tissues.</p><p id="p0029" num="0029">As used herein, "parthenogenetic embryos" refers to an embryo that only contains male or female chromosomal DNA that is derived from male or female gametes. For example, parthenogenetic embryos can be derived by activation of unfertilized female gametes, e.g., unfertilized human, murine, cynomolgus or rabbit oocytes.</p><p id="p0030" num="0030">As used herein, "nuclear transfer embryo" refers to an embryo that is produced by the fusion or transplantation of a donor cell or DNA from a donor cell into a suitable recipient cell, typically an oocyte of the same or different species that is treated before, concomitant or after transplant or fusion to remove or inactivate its endogenous nuclear DNA. The donor cell used for nuclear transfer include embryonic and differentiated cells, e.g., somatic and germ cells. The donor cell may be in a proliferative cell cycle (G<sub>1</sub>, G<sub>2</sub>, S or M) or non-proliferating (G<sub>o</sub> or quiescent). Preferably, the donor cell or DNA from the donor cell is derived from a proliferating mammalian cell culture, e.g., a fibroblast cell culture. The donor cell<!-- EPO <DP n="17"> --> optionally may be transgenic, i.e., it may comprise one or more genetic addition, substitution or deletion modifications.</p><p id="p0031" num="0031">As used herein, the term "gene" refers to the nucleotide sequences at a genetic locus that encode and regulate expression of a functional mRNA molecule or a polypeptide; i.e., as used herein, a gene includes the nucleotide sequences that make up the coding sequence (exons and introns), the promoter, enhancers, and other DNA elements that regulate transcription, including as elements conferring cell type-specific and differentiation stage-specific expression, hormone responsive elements, repressor elements, etc., and nucleotide sequences that encode signals that regulate splicing and translation of the mRNA, such as a cleavage signal, a polyadenylation signal, or an internal ribosome entry site (IRES).</p><heading id="h0012">C. <u>Providing Histocompatible Transplants To Animal or Human Recipients:</u></heading><p id="p0032" num="0032">Another object of the invention is to provide a method by which a human or non-human animal, e.g., a person in need of a cell or tissue transplant can be provided with cells or tissue suitable for transplantation that have homozygous histocompatibility antigen alletes, e.g., in the case of human recipients MHC alleles that match the MHC alleles of the person needing the transplant. The invention provides a method in which the MHC alleles of a person in need of a transplant (the recipient) are identified, and a line of stem cells homozygous for at least one MHC allele present in the recipient's cells is obtained from a stem cell bank produced according to the disclosed methods. That line of stem cells is then used to generate cells or tissue suitable for transplant that are homozygous for at least one MHC allele present in the recipient's cells. The method of the present invention further comprises grafting the cells or tissue so obtained to the body of the person in need of such a transplant. In a useful embodiment of the invention, three, four, five, six or more of the MHC alleles of the line of stem cells used to generate cells or tissue for transplant are homozygous and match MHC alleles of the transplant recipient.<!-- EPO <DP n="18"> --></p><p id="p0033" num="0033">In a useful embodiment, the line of stem cells used to generate cells or tissue suitable for transplant is a line of totipotent or nearly totipotent embryonic stem cells. In another useful embodiment, the line of stem cells used to generate cells or tissue suitable for transplant is a line of hematopoietic stem cells. The lines of stem cells that can be used to generate cells or tissue suitable for transplant are available "off the shelf" in the stem cell bank of the present invention. In a useful embodiment, the stem cell bank of the present invention comprises lines of totipotent, nearly totipotent, and/or pluripotent stem cells that are lines of rejuvenated, "hyper-youthful cells" generated by nuclear transfer techniques. In another useful embodiment, the stem cell bank of the present invention comprises one or more lines of totipotent, nearly totipotent, and/or pluripotent stem cell having DNA that is genetically modified relative to the DNA of the human donor from which they are derived. For example, the invention comprises altering genomic DNA of the cells to replace a non-homozygous MHC allele with one that is homozygous, or to inhibit the effective presentation of a class I or class II HLA antigen on the cell surface, e.g., by preventing expression of <i>β</i>2-microglobulin, or by preventing expression of one or more MHC alleles. Also, the invention encompasses introducing one or more genetic modifications that result in lineage-defective stem cells, i.e., stem cells which cannot differentiate into specific cell lineages.</p><heading id="h0013">D. <u>Methods For Making Stem Cell Lines With Homozygous MHC Alleles:</u></heading><p id="p0034" num="0034">Totipotent, nearly totipotent, and/or pluripotent stem cell lines that make up the stem cell banks of the present invention can be derived from blastocyst embryos made up of cells that are homozygous for some or all of the histocompatibility antigen alleles, e.g., MHC alleles. Blastocyst embryos useful for the present invention can be made by several different methods. In preferred embodiments of the invention, human embryos are produced by fertilization, parthenogenesis, or by same or cross-species somatic cell nuclear transfer. In the case of human embryos, for ethical reasons, they are<!-- EPO <DP n="19"> --> never allowed to develop beyond the stage of pre-implantation blastocysts of about 9-10 days before the inner cell mass cells are isolated and are cultured to produce embryonic stem (ES) cells. The cloning methods of the present invention which utilize human embryos are restricted to human therapeutic cloning techniques. The present invention does <u>not</u> include any methods that permit development of human embryos beyond the pre-implantation stage of about 9-10 days, nor does it include or contemplate reproductive cloning in any form.</p><heading id="h0014"><u>Stem cells from embryos produced by union of sperm and egg:</u></heading><p id="p0035" num="0035">In one embodiment of the invention, human or non-human stem cells are derived from embryos produced in vitro by uniting sperm and eggs by known means; for example, by in vitro fertilization (IVF) or by intracytoplasmic sperm injection (ICSI). To produce cells having homozygous MHC alleles, sperm and eggs can be obtained from individuals that are closely related; e.g., brother and sister or one determined to have similar MHC alleles. As in HLA typing for a transplant between siblings, there is about a 25% chance that an embryo produced with sibling's gametes will have matching HLA loci. The embryos produced by uniting sperm and eggs of related individuals are cultured in vitro to produce early embryo including blastocysts from which ES cells or inner cell masses are derived. HLA types of the resulting pluripotent cell lines are determined by known means; e.g., by PCR, or by culturing a sample of the cells under conditions that induce differentiation, and performing serological testing of the cells using antibodies against specific HLA antigens. Pluripotent cell lines having one or more homozygous MHC alleles are then selected for inclusion in the stem cell bank. Embryos produced by union of sperm and egg have normal genetic imprinting, i.e., they have the epigenetic contributions of both male and female parents, so they develop to form blastocysts from which pluripotent cells can be derived with high efficiency.<!-- EPO <DP n="20"> --></p><p id="p0036" num="0036">In the case where sperm and egg donors are not closely related sperm can be banked from individuals with characterized MHC loci and used for IVF or ICSI fertilization of oocytes that also have characterized MHC loci to produce embryos and stem cells with a high likelihood of generating homozygosity in the MHC loci.</p><p id="p0037" num="0037">Persons skilled in the art would recognize that the human embryos produced by uniting sperm and eggs of closely related individuals according to the present invention may be viable and could be implanted into human females to make pregnancies and develop to live births of humans having homozygous HLA alleles. This would be highly unethical, in view of the known risks to the health of the child that result from close inbreeding. As stated above, the present invention expressly does not comprise allowing the embryos to develop beyond blastocysts of about 9-14 days.</p><heading id="h0015"><u>Stem cells produced by parthenogenesis:</u></heading><p id="p0038" num="0038">In another embodiment of the invention, totipotent and pluripotent human stem cells are derived from embryos produced by parthenogenesis. The stem cells obtained by this method are diploid, because extrusion of the second polar body following parthenogenetic activation is inhibited. Methods for producing a diploid human embryo by parthenogenesis, for culturing the embryo in vitro to form a blastocyst, and for culturing cells of the blastocyst to obtain stem cells, are described in co-owned and co-pending PCT Application <patcit id="pcit0002" dnum="US0237899W"><text>PCT/US02/37899</text></patcit> (Methods for Making and Using Reprogrammed Human Somatic Cell Nuclei and Autologous and Isogenic Stem Cells) filed November 26, 2002, the disclosure of which is incorporated herein by reference in its entirety. Similar methods for producing diploid embryos by parthenogenesis using oocytes of rhesus monkeys and cynomolgous monkeys have been described by <nplcit id="ncit0006" npl-type="s"><text>Mitalipov et al. (2001, Biology of Reproduction, 65:253-259</text></nplcit>) and <nplcit id="ncit0007" npl-type="s"><text>Cibelli et al. (2002, Science, 295:81</text></nplcit>), respectively, the contents of both of which are incorporated herein by reference in their entirety.<!-- EPO <DP n="21"> --></p><p id="p0039" num="0039">In general, production of a diploid human embryo by parthenogenesis comprises
<ol><li>a. obtaining oocytes from human donors induced to superovulate by treatment with gonadotropins followed by hCG injection;</li><li>b. activating the oocytes at about 38-45 hours after hCG stimulation;</li><li>c. exposing the activated oocytes to chemical treatment that inhibits extrusion of the second polar body; and</li><li>d. culturing the embryo in vitro under conditions resulting in formation of a blastocyst.</li></ol>
Oocyte activation is normally mediated by oscillations of intracellular Ca<sup>+2</sup> ion triggered by the sperm cell. Parthenogenetic activation of the oocytes can be achieved by any of the known means for inducing oocyte activation. Such methods generally involve exposing the oocyte to ethanol, electroporation, calcium ionophore, ionomycin, or inositol 1,4,5-triphosphate to increase the intracellular Ca<sup>+2</sup> ion concentration in the oocyte, in combination with a treatment that temporarily inhibits protein synthesis or protein phosphorylation. For example, Mitalipov et al. (supra, p. 254) describe two such methods that result in production of diploid parthenogenetic blastocysts from oocytes of rhesus monkeys. In one method, the oocytes are incubated briefly in medium containing ionomycin and calcium, followed by incubation for several hours in medium containing 6-aminomethylpurine (DMAP), an inhibitor of protein phosphorylation. In the other method, the oocytes are electroporated three times in medium containing calcium, and between each electroporation, the oocytes are incubated for about 30 minutes in medium containing cycloheximide, an inhibitor of protein synthesis, and cytochalasin B, an inhibitor of microfilament synthesis.</p><p id="p0040" num="0040">Using a similar method Cibelli et al. (supra) parthenogenetically activated oocytes of a cynomolgous monkey; cultured the activated oocytes in vitro to produce a diploid blastocysts; and isolated a line of diploid ES cells from cells of the inner cell mass of a parthenogenesis-derived embryo; and showed that the ES cells are capable of differentiating into cell types of all<!-- EPO <DP n="22"> --> three embryonic germ layers. This is also described in <patcit id="pcit0003" dnum="US09697297B"><text>U.S. Serial No. 09/697,297 by Cibelli et al</text></patcit>, which is incorporated by reference in its entirety here.</p><p id="p0041" num="0041">Oocytes are obtained from women having MHC alleles of the type needed for the stem cell bank. The oocytes are parthenogenetically activated and are cultured to form blastocysts. Using known methods, the inner cell mass cells of the blastocysts are cultured in vitro to generate diploid embryonic stem cells. Because extrusion of the second polar body after meiosis II was prevented, the homologous chromosomes of such ES cells are actually the sister chromatids that were joined together as a dyad during meiosis I. Since the sister chromatids were formed by replication of a single set of chromosomes at the outset of meiosis, they will have identical DNA sequences, except for those regions that were exchanged with the homologous dyad during the recombination stage of meiosis. The HLA genes of the MHC are tightly linked, and recombination in this region is rare. occurring with a frequency of about 1%. The two sets of homozygous HLA alleles in the parthenogenetically-derived stem cell lines obtained with oocytes from a given donor reflect the HLA haplotypes of the maternal and paternal copies of chromosome 6 that the donor inherited from her parents. Known screening methods can be performed to identify the cell lines that have non-homozygous HLA antigens due to genetic recombination, and to identify the homozygous HLA alleles of each stem cell line.</p><heading id="h0016"><u>Stem cells produced by haplodization:</u></heading><p id="p0042" num="0042">In another embodiment of the invention, totipotent and pluripotent human stem cells are derived from embryos produced by union of two haploids that are homozygous for one or more MHC alleles.</p><p id="p0043" num="0043">Methods for producing embryos by fusion of two haploid genomes are described in U.S. Serial No. _______, __________ (Attorney Docket No. 015837-0291871), filed on March 14, 2003 entitled, "Use of Haploid Genome<!-- EPO <DP n="23"> --> for Genetic Diagnosis, Modification and Multiplications"), which is incorprated by reference in its entirety herein.</p><p id="p0044" num="0044">A bank of stem cell lines according to the present invention can be obtained by screening the population and identifying individuals having cells which express desired MHC antigens, and obtaining donations of the somatic cells from these individuals. However, individuals that are homozygous for MHC antigens are rare, because they are only found in inbred population. Thus, the useful embodiment of the invention is utilization of heterozygous donor cells to create homozygous stem cells.</p><p id="p0045" num="0045">In this method, somatic cells are introduced into enucleated human oocytes, and the newly constructed oocytes are activated to induce haplodization (<nplcit id="ncit0008" npl-type="s"><text>Tesarik et al., 2001 RB Online. 2:160-164</text></nplcit>), <nplcit id="ncit0009" npl-type="s"><text>Lachem-Kaplan et al, 2001 RB Online 3: 205-211</text></nplcit>. When a protocol for primate oocyte activation are used, approximately 90% of eggs yield pseudo-polar body (<nplcit id="ncit0010" npl-type="s"><text>Shoukhrat et al, 2001 Biol Reprod 65:253-259</text></nplcit>). These pseudo-polar bodies are used for genotyping using well established techniques. Other haploid embryos also can be constructed by transferring cells from other donors using the same protocol. Or the donor oocytes can be screened for the presence of desired MHC allele after activation to generate haploid oocytes. Screening of the first polar bodies will reveal the genotype of the oocytes as in above the reconstructed eggs. The activation can be done chemically and/or by injecting sperm factors (see <patcit id="pcit0004" dnum="US19108900P"><text>U.S. Application No 60/191,089 of Rafael Fissore filed March 22, 2000</text></patcit> incorporated by reference in its entirety herein) easily unless 2<sup>nd</sup> polar body extrusion is blocked systematically (incorporated by reference in its entirety herein). The remaining pronuclei are transferred to construct diploid embryos by pronuclear transfer techniques. These techniques have been well established and used widely in developmental biology fields for more than a decade. To avoid possible imprinting disturbance, morula stage human embryo lysates are injected into the newly constructed eggs. These embryo lysates are known to have ability to modify imprinting status of murine androgenone so effectively to make live born animals, otherwise develop very<!-- EPO <DP n="24"> --> poorly in vitro and died out after implantation (<nplcit id="ncit0011" npl-type="s"><text>Hagemman and First, 1992 Development 114:997-1001</text></nplcit>)</p><p id="p0046" num="0046">More particularly, the invention includes methods for generating stem cells by haplodization comprising the steps of:
<ol><li>a. Inserting a somatic donor cell, or the nucleus of such a cell, into an oocyte that is free of oocyte genomic DNA.</li><li>b. Activation of the reconstructed embryos to expel haploidal genome into a psudopolar body.</li><li>c. Screening of the psudopolar body for the genotyping of remaining pronucleus.</li><li>d. Union of the two pronuclei to generate diploid embryos by pronuclei transfer. Or alternatively, transferring a pronucleus to an activated haploid oocyte which has desired haploid genome</li><li>e. Injection of human morular stage embryo lysates to the reconstructed embryos.</li><li>f. Culturing embryo and generating stem cells/or differentiated cells or tissue needed for transplant from cells of said embryos.</li></ol></p><p id="p0047" num="0047">In addition, haploid genomes can be derived by other means known in the art, including the use of the first and second polar bodies. While occasionally, such DNA is fragmented, intact genomes can be obtained as evidenced by the production of live mice from polar body DNA (<nplcit id="ncit0012" npl-type="s"><text>Wakayama, T., and Yanagimachi, R. Biol. Reprod. 1998. 59(1) 100-4</text></nplcit>) and these haploid or diploid genomes can be used as described above.</p><heading id="h0017"><u>Stem cells produced by cytoplasm transfer:</u></heading><p id="p0048" num="0048">Totipotent and pluripotent stem cells homozygous for histocompatibility antigens, e.g., MHC antigens can also be produced by transferring cytoplasm from an oocyte or an ES cell into a somatic cell that is homozygous for MHC antigens, so that the chromatin of the somatic cell is reprogrammed and the somatic cell de-differentiates to generate a pluripotent or totipotent stem cell. Methods for converting differentiated cells into de-differentiated, pluripotent, stem<!-- EPO <DP n="25"> --> or stem-like cells that can be induced to re-differentiate into a cell type other than that of the initial differentiated cells, are described in co-owned and co-pending <patcit id="pcit0005" dnum="US73626800A"><text>U.S. Application No. 09/736,268 , filed December 15, 2000</text></patcit>, and <patcit id="pcit0006" dnum="US11293902A"><text>U.S. Application No. 10/112,939 filed April 2, 2002</text></patcit>, both by Karen B. Chapman, the disclosures of both of which are incorporated herein by reference in their entirety.</p><heading id="h0018"><u>Stem cells from embryos produced by nuclear transfer:</u></heading><p id="p0049" num="0049">In another embodiment of the invention, totipotent, nearly totipotent, and/or pluripotent human stem cells that are homozygous for one or more MHC alleles are derived from embryos produced in vitro by somatic cell nuclear transfer techniques. The totipotent and/or pluripotent stem cells generated by this embodiment of the invention will have the genomic DNA of the somatic donor cell used for nuclear transfer. When the somatic donor cell is homozygous for an MHC allele, the stem cells generated by nuclear transfer cloning will also be homozygous for the MHC allele.</p><p id="p0050" num="0050">A bank of stem cell lines according to the present invention can be obtained by screening a species, preferably human population and identifying individuals that are homozygous for clinical MHC antigens, and obtaining donations of somatic cells from these individuals. Individuals having homozygous MHC alleles are often found in inbred populations. Alternatively, somatic cells, preferably human, homozygous for MHC loci that are useful for the present invention can be produced by obtaining somatic cells that are heterozygous for an MHC allele, and genetically altering the DNA of the cells using known methods so that they are homozygous for one or more MHC loci. This can be done, for example, by using well-known homologous recombination techniques to replace a non-homozygous MHC allele with one that is homozygous.</p><p id="p0051" num="0051">In a useful embodiment of the invention, donors of somatic cells to be used in nuclear transfer according to the present invention may be selected to provide cells that are relatively resistant to blood cell cancers, for use in reconstituting the blood of blood cancer patients. Such blood cells can be<!-- EPO <DP n="26"> --> chosen based on their natural killer (NK) cell phenotype. The somatic cell donors who having resistance to blood cell cancers can be selected to have homozygous MHC alleles, or the donated cells can be genetically altered to have one or more homozygous MHC alleles as discussed above.</p><p id="p0052" num="0052">The donated cells are cloned by nuclear transfer techniques that result in production of blastocyst embryos from which are obtained totipotent and/or pluripotent stem cells that are homozygous for one or more MHC loci. For each cell line to be produced, a somatic donor cell that is homozygous for a MHC allele, or the the nucleus or set of chromosomes of such a cell, is inserted into a human oocyte that is coordinately enucleated to produce a nuclear transfer unit that develops as an embryo. The embryo is cultured ex vivo to the blastocyst stage, and totipotent and/or pluripotent stem cells are derived from inner cell mass (ICM) cells of the embryo that have the genomic DNA of the donor cell. In a useful embodiment, the stem cell bank comprises totipotent, nearly totipotent ES cells homozygous for MHC antigens. Totipotent and pluripotent stem cells homozygous for various combinations of MHC antigens are assembled and maintained as a bank of cells available for therapeutic transplantation.</p><p id="p0053" num="0053">Methods for transferring the nuclear DNA of a somatic cell of a patient into an oocyte to effect the reprogramming of the chromatin and produce an NT unit from which are generated pluripotent stem cells and totipotent ES cells are described, for example, in co-owned and co-pending <patcit id="pcit0007" dnum="US65581500A"><text>U.S. Application No. 09/655,815 filed September 6, 2000</text></patcit>; and <patcit id="pcit0008" dnum="US79768401A"><text>U.S. Application No. 09/797,684 filed March 5, 2001</text></patcit>; and also in PCT Application No. <patcit id="pcit0009" dnum="US0237899W"><text>PCT/US02/37899</text></patcit> (Methods for Making and Using Reprogrammed Human Somatic Cell Nuclei and Autologous and Isogenic Stem Cells) filed November 26, 2002, the disclosures of all three of which are incorporated herein by reference in their entirety. Similar methods are described in co-owned and co-pending <patcit id="pcit0010" dnum="US52702600A"><text>U.S. Application Nos. 09/527,026 filed March 16, 2000</text></patcit>, <patcit id="pcit0011" dnum="US09520879B"><text>09/520,879 filed April 5, 2000</text></patcit>, and <patcit id="pcit0012" dnum="US09656173B"><text>09/656,173 filed September 6, 2000</text></patcit>, the disclosures of which are incorporated herein by reference in their entirety. In<!-- EPO <DP n="27"> --> general, methods for cloning by somatic cell nuclear transfer to produce stem cells for generating cells or tissue useful for transplantation comprise the steps of:
<ol><li>a. inserting a somatic donor cell, or the nucleus of such a cell, into an oocyte and removing the oocyte genomic DNA (enucleation) under conditions that produce an activated nuclear transfer unit that develops as an embryo; and</li><li>b. generating stem cells and/or differentiated cells or tissue needed for transplant from cells of said embryo.</li></ol>
Such a method can be used to generate lines of totipotent or nearly totipotent ES cells that can be cultured under conditions in which they differentiate into specific, recognized cell types. Such ES cells have the capacity to differentiate into every cell type of the body, including the germ cells. The stem cells produced by somatic cell nuclear transfer have the patient's genomic DNA, so the differentiated cells and tissues generated from such stem cells are nearly completely autologous - all of the cells' proteins , are encoded by the patient's own DNA except for those proteins encoded by the cells' mitochondria, which derive from the oocyte. Accordingly, differentiated cells and tissues generated from stem cells produced by nuclear transfer methods can be transplanted to the person who provided the nuclear donor cell without triggering the severe rejection response that results when foreign cells or tissue are transplanted.</p><p id="p0054" num="0054">As described in the above-identified co-pending applications, the somatic donor cell used for nuclear transfer to produce human stem cells homozygous for a MHC allele according to the present invention can be of any somatic cell type in the body. For example, the somatic donor cell can be a cell selected from the group consisting of fibroblasts, B cells, T cells, dendritic cells, keratinocytes, adipose cells, epithelial cells, epidermal cells, chondrocytes, cumulus cells, neural cells, glial cells, astrocytes, cardiac cells, esophageal cells, muscle cells, melanocytes, hematopoietic cells, macrophages, monocytes, and mononuclear cells. The somatic donor cell<!-- EPO <DP n="28"> --> can be obtained from any organ or tissue in the body; for example, it can be a cell from an organ selected from the group consisting of liver, stomach, intestines, lung, stomach, intestines, lung, pancreas, cornea, skin, gallbladder, ovary, testes, kidneys, heart, bladder, and urethra.</p><p id="p0055" num="0055">Methods for generating rejuvenated, "hyper-youthful" stem cells and differentiated somatic cells having the genomic DNA of a human somatic donor cell are described in co-owned and co-pending <patcit id="pcit0013" dnum="US52702600A"><text>U.S. Application Nos. 09/527,026 filed March 16, 2000</text></patcit>, <patcit id="pcit0014" dnum="US09520879B"><text>09/520,879 filed April 5, 2000</text></patcit>, and <patcit id="pcit0015" dnum="US09656173B"><text>09/656,173 filed September 6, 2000</text></patcit>, the disclosures of which have been incorporated herein by reference in their entirety. For example, rejuvenated, "hyper-youthful" stem cells having the genomic DNA of a human somatic cell donor can be produced by a method comprising:
<ol><li>a. isolating normal, somatic cells from a human donor, and passaging or otherwise inducing the cells into a state of checkpoint-arrest, senescence, or near-senescence,</li><li>b. transferring a checkpoint-arrested, senescent, or near-senescent donor cell, the nucleus of said cell, or chromosomes of said cell, into a recipient oocyte, and coordinately removing the oocyte genomic DNA from the oocyte, to generate an embryo; and</li><li>c. generating rejuvenated stem cells from said embryo having the genomic DNA of the donor cell.</li></ol></p><p id="p0056" num="0056">As described in the above-identified co-pending applications, the pluripotent and totipotent stem cells homozygous for a MHC allele of the present invention that are produced by nuclear transfer using a checkpoint-arrested, senescent, or near-senescent donor cell are rejuvenated cells that are distinguished from other cells in having telomeres that are longer than the corresponding telomeres of the checkpoint-arrested, senescent, or near-senescent donor cell. Moreover, the telomeres of such rejuvenated cells are on average at least as long as the telomeres of age-matched control cells of the same type and species that are not generated by nuclear transfer techniques. In addition, the nucleotide sequences of the tandem (TTAGGG)<sub>n</sub><!-- EPO <DP n="29"> --> repeats that comprise the telomeres of such rejuvenated cells are more uniform and regular; i.e., have significantly fewer non-telomeric nucleotide sequences, than are present in the telomeres of age-matched control cells of the same type and species that are not generated by nuclear transfer. Such rejuvenated cells are "hyper-youthful", in that the proliferative life-span of the rejuvenated cells is at least as long as, and is typically longer than, the proliferative life-span of age-matched control cells of the same type and species that are not generated by nuclear transfer techniques. Such rejuvenated cells also have patterns of gene expression that are characteristic of youthful cells; for example, activities of EPC-1 and telomerase in such rejuvenated cells are typically greater than EPC-1 and telomerase activities in age-matched control cells of the same type and species that are not generated by nuclear transfer techniques.</p><p id="p0057" num="0057">As described in the above-identified co-pending applications, rejuvenated totipotent and/or pluripotent stem cells can be generated from an embryo produced by nuclear transfer by methods comprising obtaining a blastocyst, an embryonic disc cell, inner cell mass cell, or a teratoma cell using said embryo, and generating the pluripotent and/or totipotent stem cells from said blastocyst, inner cell mass cell, embryonic disc cell, or teratoma cell.</p><p id="p0058" num="0058">As described in co-owned and co-pending <patcit id="pcit0016" dnum="US68506100A"><text>U.S. Application Nos. 09/685,061 filed October 6, 2000</text></patcit>, <patcit id="pcit0017" dnum="US09809018B"><text>09/809,018 filed March 16, 2001</text></patcit>, and <patcit id="pcit0018" dnum="US09874040B"><text>09/874,040 filed June 6, 2001</text></patcit>, the recipient oocyte may be derived from a non-human mammal. For example, the oocyte may be from a mammal selected from the group consisting of sheep, bovines, ovines, pigs, horses, rabbits, guinea pigs, mice, hamsters, rats, and non-human primates. In a preferred embodiment, the oocyte is from a bovine mammal, or a rabbit. A stem cell line having the genome of a human cell that is derived using a non-human oocyte is referred to herein as a "human" stem cell line, even though the mitochondria of such cells are of a non-human type.<!-- EPO <DP n="30"> --></p><heading id="h0019"><u>Genetically modified stem cells:</u></heading><p id="p0059" num="0059">The methods of the present invention include producing totipotent and/or pluripotent stem cells homozygous for MHC antigens that are genetically modified relative to the cells of the human donor from which they were originally obtained. The stem cells can be genetically modified in any manner that enhances or improves the overall efficiency by which cells for transplant are produced and the therapeutic efficacy of the cell transplantation. Methods that use recombinant DNA techniques to introduce modifications at selected sites in the genomic DNA of cultured cells are well known. Such methods can include (1) inserting a DNA sequence from another organism (human or non-human) into target nuclear DNA, (2) deleting one or more DNA sequences from target nuclear DNA, and (3) introducing one or more base mutations (e.g., site-directed mutations) into target nuclear DNA. Such methods are described, for example, in <nplcit id="ncit0013" npl-type="b"><text>Molecular Cloning, a Laboratory Manual, 2nd Ed., 1989, Sambrook, Fritsch, and Maniatis, Cold Spring Harbor Laboratory Press</text></nplcit>; <patcit id="pcit0019" dnum="US5633067A"><text>U.S. Pat. No. 5,633,067</text></patcit>, "Method of Producing a Transgenic Bovine or Transgenic Bovine Embryo," DeBoer et al., issued May 27, 1997; <patcit id="pcit0020" dnum="US5612205A"><text>U.S. Pat. No. 5,612,205</text></patcit>, "Homologous Recombination in Mammalian Cells," Kay et al., issued Mar. 18, 1997; and <patcit id="pcit0021" dnum="WO9322432A"><text>PCT publication WO 93/22432</text></patcit>, "Method for Identifying Transgenic Pre-Implantation Embryos," all of which are incorporated by reference herein in their entirety. Such methods include techniques for transfecting cells with foreign DNA fragments and the proper design of the foreign DNA fragments such that they effect insertion, deletion, and/or mutation of the target DNA genome. For example, known methods for genetically altering cells that use homologous recombination can be used to insert, delete, or rearrange DNA sequences in the genome of a cell of the present invention. A genetic system that uses homologous recombination to modify targeted DNA sequences in a mammalian cell to "knock-out" a cell's ability to express a selected gene is disclosed by <patcit id="pcit0022" dnum="US5631153A"><text>Capecchi et al. in U.S. Patent Nos. 5,631,153</text></patcit> and <patcit id="pcit0023" dnum="US5464764A"><text>5,464,764</text></patcit>, the contents of which are incorporated herein in their entirety. Such known<!-- EPO <DP n="31"> --> methods can be used to insert into the genomic DNA of a cell an additional (exogenous) DNA sequence comprising an expression construct containing a gene that is to be expressed in the modified cell. The gene to be expressed can be operably linked to any of a wide variety of different types of transcriptional regulatory sequences that regulate expression of the gene in the modified cell. For example, the gene can be under control of a promoter that is constitutively active in many different cell types, or one that is developmentally regulated and is only active in one or a few specific cell types. Alternatively, the gene can be operably linked to an inducible promoter that can be activated by exposure of the cell to a physical (e.g., cold, heat, light, radiation) or chemical signal. Many such inducible promoters and methods for using them effectively are well known. Examples of the characteristics and use of such promoters, and of other well-known transcriptional regulatory elements such as enhancers, insulators, and repressors, are described, for example, in <nplcit id="ncit0014" npl-type="b"><text>Transgenic Animals, Generation and Use, 1997, edited by L. M. Houdebine, Hardwood Academic Publishers, Australia</text></nplcit>, the contents of which are incorporated herein by reference.</p><p id="p0060" num="0060">Stem cells homozygous for MHC antigens that have multiple genetic alterations can be produced using known methods. For example, one can produce cells that are modified at multiple loci, or cells that are modified at a single locus by complex genetic alterations requiring multiple manipulations. To produce stem cells having multiple genetic alterations, it is useful to perform the genetic manipulations on somatic cells cultured in vitro, and then to clone the genetically altered cells by somatic cell nuclear transfer and generate ES cells having multiple genetic alterations from the resulting blastocysts. Methods for generating genetically modified cells using nuclear transfer cloning techniques are described, for example, in co-owned and co-pending <patcit id="pcit0024" dnum="US52702600A"><text>U.S. Application Nos. 09/527,026 filed March 16, 2000</text></patcit>, <patcit id="pcit0025" dnum="US09520879B"><text>09/520,879 filed April 5, 2000</text></patcit>, and <patcit id="pcit0026" dnum="US09656173B"><text>09/656,173 filed September 6, 2000</text></patcit>, the disclosures of which have been incorporated herein by reference in their entirety.<!-- EPO <DP n="32"> --></p><p id="p0061" num="0061">Alternatively, the totipotent and/or pluripotent stem cells having homozygous MHC alleles that are produced by any of the methods described above can be genetically modified directly using known methods. For example, Zwaka et al. have described a method for genetically modifying human ES cells in vitro by homologous recombination (<nplcit id="ncit0015" npl-type="s"><text>Nature Biotechnology, Vol. 21, No. 3, March, 2003</text></nplcit>).</p><p id="p0062" num="0062">In generating stem cells by nuclear transfer, it is useful to genetically modify the nuclear donor cell to enhance the efficiency of embryonic development and the generation of ES cells. The gene products of the Ped type, which are members of the Class I MHC family and include the Q7 and Q9 genes, are reported to enhance the rate of embryonic development. Modification of the DNA of nuclear donor cells by insertion of DNA expression contructs that provide for the expression of these genes, or their human counterparts, will give rise to nuclear transfer embryos that grow more quickly. It appears that these genes are only expressed early in blastocyst development and so are not expected to be disruptive of later development.</p><p id="p0063" num="0063">The efficiency of embryonic development can also be enhanced by genetically modifying the nuclear donor cell to have increased resistance to apoptosis. Genes that induce apoptosis are reportedly expressed in preimplantation stage embryos (<nplcit id="ncit0016" npl-type="s"><text>Adams et al, Science, 281 (5381):1322-1326 (1998</text></nplcit>). Such genes include Bad, Bok, BH3, Bik, Hrk, BNIP3, Bim<sub>L</sub>, Bad, Bid, and EGL-1. By contrast, genes that reportedly protect cells from programmed cell death include BcL-XL, Bcl-w, Mcl-1, A1, Nr-13, BHRF-1, LMW5-HL, ORF16, Ks-Bel-2, E1B-19K, and CED-9. Nuclear donor cells can be constructed in which genes that induce apoptosis are "knocked out" or in which the expression of genes that protect the cells from apoptosis is enhanced or turned on during embryonic development. Expression constructs that direct synthesis of antisense RNAs or ribozymes that specifically inhibit expression of genes that induce apoptosis during early embryonic development can also be inserted into the DNA of nuclear donor cells to enhance development of nuclear transfer-derived embryos.<!-- EPO <DP n="33"> --> Apoptosis genes that may be expressed in the antisense orientation include BAX, Apaf-1, and capsases. Many DNAs that promote or inhibit apoptosis have been reported and are the subject of numerous patents. The construction and selection of genes that affect apoptosis, and of cell lines that express such genes, is disclosed in <patcit id="pcit0027" dnum="US5646008A"><text>U.S. Patent No. 5,646,008</text></patcit>, the contents of which are incorporated herein by reference.</p><p id="p0064" num="0064">Stem cells can be produced that are genetically modified grow more efficiently in tissue culture than unmodified cells; e.g., by increasing the number of growth factor receptors on the cells' surface. Use of stem cells having such modifications reduces the time required to generate an amount of cells for transplant that is sufficient to have therapeutic effect.</p><p id="p0065" num="0065">The histocompatibility of a line of cells to be used for transplant with a patient in need of such as transplant may be increased by altering the genomic DNA of the cells to replace a non-homozygous MHC allele with one that is homozygous and matches an HLA allele of the patient. Alternatively, the genomic DNA of the cells can be modified to inhibit the effective presentation of a class I or class II HLA antigen on the cell's surface; for example, by introducing a genetic alteration that prevents expression of <i>β</i>2-microglobulin, which is an essential component of class I HLA antigens; by introducing genetic alterations in the promoter regions of the class I and/or or class II MHC genes; or simply by deleting a portion of the DNA of one or more of the class I and/or or class II MHC genes sufficient to prevent expression of the gene(s).</p><p id="p0066" num="0066">Stem cells of the invention can be genetically modified (e.g., by homologous recombination) to have a heterozygous knock-out of the Id1 gene, and a homozygous knockout of the Id3 gene. As described in co-owned and co-pending PCT Application No. PCT/USU3/01827 (Stem Cell-Derived Endothelial Cells Modified to Disrupt Tumor Angiogenesis), filed January 22, 2003, these stem cells can be induced to differentiate into Id1+/-, Id3 -/- endothelial cell precursor cells that are useful for the treatment of<!-- EPO <DP n="34"> --> cancer because they give rise to endothelial cells that disrupt and inhibit tumor angiogenesis.</p><p id="p0067" num="0067">Stem cells of the invention can also be genetically modified to provide a therapeutic gene product that the patient requires, e.g., due to an inborn error of metabolism. Many genetic diseases are known to result from an inability of a patient's cells to produce a specific gene product. The present invention making genetically altered stem cells that can be used to produce cells with homozygous MHC alleles for transplantation that are genetically modified to synthesize enhanced amounts of a gene product required by the transplant recipient. For example, hematopoietic stem cells that are genetically altered to produce and secrete adenosine deaminase can be prepared for transplant to a patient suffering from adenosine deaminase deficiency. The methods of the present invention permit production of such cells without the use of recombinant retrovirus, which can insert at a site in the genomic DNA that disrupts normal growth control and causes neoplastic transformation.</p><p id="p0068" num="0068">Stem cells of the invention can also be genetically modified by introduction of a gene that causes the cell to die. The gene can be put under control of in inducible promoter. If for any reason the transplanted cells react in a in a way that can harm the recipient, expression of the suicide genes can be induced to kill the transplanted cells. Use of inducible suicide genes in this manner is known in the art. Suitable suicide genes include genes encoding HSV thymidine kinase and cytodine deaminase, with which cell death is induced by gancyclovir and 5-fluorocytosine, respectively.</p><p id="p0069" num="0069">The cells may be modified to knockout one or more histocompatibility antigen alletes, e.g., MHC alleles such that only one set remains. This leads to an underexpression of the MHC genes, but a phenotype effective in reducing the complexity of the MHC serotype and effective in producing cells capable of otherwise functioning and useful in the treatment of disease. Alternatively, homozygosity can be engineered into the cell lines by the targeted introduction of the appropriate alleles to the nonhomologous set, to<!-- EPO <DP n="35"> --> result in homozygosity. In addition, the chromosome carrying the MHC genes can be removed from cells by laser ablation and a chromosome carrying the identical chromosome as remains in the cell can be added by microsome-mediated chromosome transfer, or by other techniques known in the art.</p><p id="p0070" num="0070">The present invention is by no means limited to the foregoing examples of genetic alterations. Persons skilled in the art will be able to identify numerous other ways by which stem cells produced according to the present invention can be genetically modified to enhance their utility.</p><heading id="h0020"><u>Preparing totipotent and/or pluripotent stem cells:</u></heading><p id="p0071" num="0071">Stem cells are present in the earliest stages of embryo formation.<br/>
Embryonic stem cells (ES cells) are undifferentiated stem cells that are derived from the inner cell mass (ICM) of a blastocyst embryo. Totipotent and/or nearly totipotent ES cell lines can be derived from human blastocysts using known methods comprising removing cells of the inner cell mass of an early blastocyst by microsurgery or immuno-surgery and culturing the cells in vitro (e.g., see <patcit id="pcit0028" dnum="US6235970B"><text>U.S. Patent No. 6,235,970</text></patcit>, the contents of which are incorporated herein by reference in their entirety). For example, such methods are described in co-owned and co-pending PC7 application, <patcit id="pcit0029" dnum="US0237899W"><text>PCT/US02/37899</text></patcit> (Methods for Making and Using Reprogrammed Human Somatic Cell Nuclei and Autologous and Isogenic Stem Cells) filed November 26, 2002, using blastocysts produced both by nuclear transfer and by parthenogenesis, the disclosure of which are incorporated herein by reference in its entirety. Thomson et al. also describes methods by which ES cell lines can be derived from primate/human blastocysts (<nplcit id="ncit0017" npl-type="s"><text>Science, 1988, 282:1145-1147</text></nplcit>; and <nplcit id="ncit0018" npl-type="s"><text>Proc. Natl. Acad. Sci., USA, 1995, 92:7544-7848</text></nplcit>), which are incorporated by reference herein in their entirety. A detailed method for preparing human ES cells is also described in Thomson's <patcit id="pcit0030" dnum="US6200806B"><text>U.S. Patent No. 6,200,806</text></patcit>, "Primate Embryonic Cells," issued March 13, 2001, the disclosure of which is incorporated herein by reference in its entirety. As described therein, a<!-- EPO <DP n="36"> --> human ES cell line can be derived from cells of a blastocyst by a method comprising:
<ol><li>a. isolating a human blastocyst;</li><li>b. isolating cells from the inner cell mass of the blastocyst;</li><li>c. plating the inner cell mass cells on embryonic fibroblasts so that inner-cell mass-derived cell masses are formed;</li><li>d. dissociating the mass into dissociated cells;</li><li>e. replating the dissociated cells on embryonic feeder cells;</li><li>f. selecting colonies with compact morphologies and cells with high nucleus to cytoplasm ratios and prominent nucleoli; and</li><li>g. culturing the selected cells to generate a pluripotent human embryonic stem cell line.</li></ol>
Methods for growing human ES cells and maintaining them in an undifferentiated state without culturing them on a layer of feeder cells have also been described (<nplcit id="ncit0019" npl-type="s"><text>Xu et al., Nature Biotechnology, 2001, 19:971-4</text></nplcit>, the contents of which are incorporated herein by reference in their entirety). Feeder-free culture of stem cells can reduce the risk of contamination of the cells by pathogens that may reside in the feeder cells.</p><heading id="h0021"><u>Generating differentiated cells:</u></heading><p id="p0072" num="0072">Stem cells are widely regarded as an abundant source of pluripotent cellular material that can be directed to differentiate into cells and tissues that are suitable for transplantation into patients in need of such cell and tissue transplants. ES cells appear to have unlimited proliferative potential and are capable of differentiating into all of the specialized cell types of a mammal, including the three embryonic germ layers (endoderm, mesoderm, and ectoderm), and all somatic cell lineages and the germ line. Using known methods, totipotent or nearly totipotent ES cells can be cultured under conditions in which they differentiate into pluripotent or multipotent stem cells such as hematopoietic or neuronal stem cells. Alternatively, totipotent ES cells can be cultured under conditions in which they differentiate into a<!-- EPO <DP n="37"> --> terminally differentiated cell type such as a cardiac muscle cell. Totipotent and/or pluripotent stem cells homozygous for MHC alleles produced by the methods of the present invention can be cultured using methods and conditions known in the art to generate cell lineages that differentiate into many, if not all, of the cell types of the body, for transplant into human patients in need of such transplants. Such stem cells having one or more homozygous MHC alleles can differentiate into cells selected from the group consisting of immune cells, neurons, skeletal myoblasts, smooth muscle cells, cardiac muscle cells, skin cells, pancreatic islet cells, hematopoietic cells, kidney cells, and hepatocytes. For example, methods have been described by which totipotent or nearly totipotent ES cells are induced to differentiate in vitro into cardiomyocytes (<nplcit id="ncit0020" npl-type="s"><text>Paquin et al., Proc. Nat. Acad. Sci. (2002) 99:9550-9555</text></nplcit>), hematopoietic cells (<nplcit id="ncit0021" npl-type="s"><text>Weiss et al., Hematol. Oncol. Clin. N. Amer. (1997) 11(6):1185-98</text></nplcit>; also <patcit id="pcit0031" dnum="US6280718B"><text>U.S. Patent No. 6,280,718</text></patcit>), insulin-secreting beta cells (<nplcit id="ncit0022" npl-type="s"><text>Assady et al., Diabetes (2001) 50(8):1691-1697</text></nplcit>), and neural progenitors capable of differentiating into astrocytes, oligodendrocytes, and mature neurons (<nplcit id="ncit0023" npl-type="s"><text>Reubinoff et al., Nature Biotechnology (2001) 19:1134-1140</text></nplcit>; also <patcit id="pcit0032" dnum="US5851832A"><text>U.S. Patent No. 5,851,832</text></patcit>).</p><p id="p0073" num="0073">Novel screening methods that make use of gene trapped cell lines and provide means for efficiently identifying combinations of biological, biochemical, and physical agents or conditions that induce stem cells to differentiate into cell types useful for transplant therapy, and for preparing and isolating specific differentiated cell types, are described in co-owned and co-pending <patcit id="pcit0033" dnum="US22728202A"><text>U.S. Application No. 10/227,282, filed August 26, 2002</text></patcit>, and in <patcit id="pcit0034" dnum="US41833302P"><text>U.S. Provisional Application No. 60/418,333</text></patcit> ("Methods Using Gene Trapped Stem Cells for Marking Pathways of Stem Cell Differentiation And Making and Isolating Differentiated Cells"), filed October 16, 2002, the contents of both of which are also incorporated herein by reference in their entirety.</p><p id="p0074" num="0074">In a useful embodiment of the present invention, a stem cell bank is produced that comprises hematopoietic stem cells homozygous for MHC antigens. A method for inducing the differentiation of pluripotent human<!-- EPO <DP n="38"> --> embryonic stem cells into hematopoietic cells useful for transplant according to the present invention is described in <patcit id="pcit0035" dnum="US6280718B"><text>U.S. Patent No. 6,280,718</text></patcit>, "Hematopoietic Differentiation of Human Pluripotent Embryonic Stem Cells," issued to Kaufman et al. on August 28, 2001, the disclosure of which is incorporated herein by reference in its entirety. The method disclosed in the patent of Kaufman et al, comprises exposing a culture of pluripotent human embryonic stem cells to mammalian hematopoietic stromal cells to induce differentiation of at least some of the stem cells to form hematopoietic cells that form hematopoietic cell colony forming units when placed in methylcellulose culture.</p><p id="p0075" num="0075">Those skilled in the art will appreciate that, using currently available methodologies, the totipotent and pluripotent stem cells of the present invention can also be used to generate tissues formed of two or more different cell types homozygous for a MHC allele, for transplant to a person in need of such a tissue transplant.</p><p id="p0076" num="0076">The pluripotent and totipotent stem cells homozygous for MHC antigens that are generated according to the present invention, and the lines of differentiated cells obtained from these stem cells, are produced and isolated under Good Manufacturing Practices (GMP) conditions.</p><heading id="h0022"><u>Providing Histocompatible Transplants To People Needing Them:</u></heading><p id="p0077" num="0077">The methods for generating stem cells and differentiated cells having homozygous MHC alleles described above provide effective solutions to many of the problems associated with obtaining cells for transplant that are histocompatible with a transplant recipient. However, de novo production of histocompatible cells and tissue for transplantation by in vitro fertilization, parthenogenesis, or nuclear-transfer-based methods for each patient in need of transplant is time-consuming. The time required to prepare "customized" cells or tissue for transplantation having the same HLA antigens as the transplant recipient can be problematic when the health of the would-be recipient is rapidly deteriorating for want of a transplant. Therefore, one or<!-- EPO <DP n="39"> --> more of the above-described methods for generating stem cells and differentiated cells having homozygous MHC alleles are used to produce a stem cell bank comprising many different lines of stem cells, each having a different combination of homozygous MHC alleles present in the population. When a patient is found to be in need of a particular type of cell transplant, a line of stem cells from the stem cell bank having homozygous MHC alleles matching those of the patient can be taken "off the shelf" and cultured under conditions causing them to differentiate into the type(s) of cells needed. The differentiated cells are then isolated using known methods, and are provided to the patient's physician for transplant.</p><p id="p0078" num="0078">Accordingly, the present invention includes the process of identifying the type of cells needed for transplant, and the blood type and HLA antigens of the transplant recipient, selecting stem cells from the stem cell bank that differentiate into the cell type needed and have homozygous HLA antigens that match those of the transplant recipient; culturing the stem cells under conditions in which they differentiate into the cell type needed; isolating the differentiated cells needed for transplant; and providing these to the patient's physician for transplant into the patient.</p><p id="p0079" num="0079">The differentiated cells for transplant produced by these methods are homozygous for at least one HLA antigen present on cells of the transplant recipient. Histocompatibility of the cells for transplant and the recipient increases as a function of the number of homozygous HLA antigens of the cells for transplant that match HLA antigens of the recipient. The greater the number of homozygous HLA antigens of the cells for transplant that match HLA antigens of the recipient, the longer the graft is expected to survive without being rejected. The cells for transplant provided by the invention will therefore have one, two, three, four, five, six, or more homozygous HLA antigens that match HLA antigens of the recipient. For example, cells for transplant produced by the present invention can have homozygous HLA-A, HLA-B, and HLA-DR antigens that match HLA antigens of the recipient. Alternatively, the cells for transplant produced by the present invention can<!-- EPO <DP n="40"> --> have homozygous HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP antigens that match HLA antigens of the recipient. The ability to select stem cells "off the shelf' to produce cells for transplant having a relatively high number of homozygous HLA antigens that match those of a prospective transplant recipient depends on the size and complexity of the stem cells bank. A stem cell bank containing from 100,000 to 200,000 different stem cell lines, each having a different combination of homozygous HLA-A, HLA-B, and HLA-DR antigens, is required in order to be able to provide cells with homozygous HLA-A, HLA-B, and HLA-DR antigens that match the corresponding HLA antigens of a large percentage of people in a diverse population such as that of North America. Use of cells from individuals with blood type O can avoid rejection based on ABO blood type; but there would have to be two versions of each cell type in the stem cell bank in order to provide matches to the Rh(+) and Rh(-) blood types. Accordingly, a stem cell bank containing several hundred thousand stem cell lines can be expected to provide "off the shelf' stem cells that can be used to generate differentiated cells needed for transplant that have homozygous HLA-A, HLA-B, and HLA-DR antigens matching those of a person in need of such a transplant.</p><p id="p0080" num="0080">The stem cell bank of the present invention contains lines of totipotent, nearly totipotent, and/or pluripotent human stem cells, each having a specific combination of one or more homozygous HLA antigens. The lines of stem cells that can be used to generate cells or tissue suitable for transplant can be lines of totipotent or nearly totipotent human ES cells. The stem cell lines can also be pluripotent, partially differentiated stem cells such as myoblasts, hematopoietic stem cells, neuronal precursor cells, and endothelial cell precursor cells.</p><heading id="h0023"><u>Therapeutic cell transplantation:</u></heading><p id="p0081" num="0081">Using the methods of the present invention, a line of totipotent or pluripotent stem cells can be selected from a bank of such stem cells that are homozygous for one or more histocompatibility antigen alleles, in the case of<!-- EPO <DP n="41"> --> human stem cells, MHC alleles that match an MHC allele of a patient in need of transplant. For example, the stem cells can have homozygous HLA-A, HLA-B, and HLA-DR alleles that match HLA-A, HLA-B, and HLA-DR alleles of the patient. The stem cells are cultured ex vivo under conditions in which they are induced to differentiate into partially or fully differentiated cell types that are suitable for transplant and have homozygous MHC alleles that match MHC alleles of the patient in need of the transplant.</p><p id="p0082" num="0082">The partially or fully differentiated cells needed for transplant are isolated from other cell types, e.g., using antibody-based separation methods such as cell sorting or immunomagnetic beads, and antibodies that are specific for one or more differentiation antigens on the surface of the cell type needed for transplant, as described in <patcit id="pcit0036" dnum="US41833302P"><text>U.S. Provisional Application No. 60/418,333, filed October 16, 2002</text></patcit>, the disclosure of which is incorporated herein by reference in its entirety. The isolated partially or fully differentiated cells are then administered by transplantation to the patient using known methods. Methods for transplantation of epidermal cells, hematopoietic stem cells, Islet of Langerhans cells, chondrocytes, hepatocytes, myoblasts, neural cells, and endothelial cells are reviewed by <nplcit id="ncit0024" npl-type="b"><text>Inverardi et al. (Transplantation Biology, Cellular and Molecular Aspects, Chapter 56, 1996, ed. by Tilney et al., Lippincott-Raven, Philadelphia, PA</text></nplcit>). The method to be used to transplant or engraft cells to a patient is recognized as depending on the type of cells to be transplanted, and on the pathology of the patient.</p><heading id="h0024"><u>Cells Homozygous for Recessive Disease-Causing Genes:</u></heading><p id="p0083" num="0083">Recessive alleles responsible for genetically inherited diseases are endemic in the population. If cells of people carrying a recessive disease-causing gene are used to produce stem cells having homozygous HLA alleles from embryos generated by parthenogenesis, or with sperm and eggs of closely related individuals, there is a relatively high likelihood that some of the stem cell lines obtained also be homozygous for the recessive disease-causing gene. The stem cell lines produced by the methods of the present<!-- EPO <DP n="42"> --> invention can therefore be screened to identify those which are homozygous for a recessive disease-causing gene. Such screening can be carried out using known methods. For example, DNA sequences of the cells can be amplified by the polymerase chain reaction (PCR) and analyzed by DNA sequencing, restriction enzyme cleavage, or by hybridization to an array of oligomers, e.g., on a microchip. Examples of recessive-disease causing genes to be screened for include, but are not limited to, of recessive genes causing the following conditions:
<ul><li>Adenosine deaminase deficiency</li><li>Albinism</li><li>Adenylosuccinate lyase deficiency</li><li>Alpha-1 antitrypsin deficiency</li><li>Cystic Fibrosis</li><li>Friedreich's ataxia</li><li>Gaucher's disease</li><li>hypercholesterolemia</li><li>Alzheimer's Disease</li><li>Autoimmune <u>p</u>olyendocrinopathy <u>c</u>andidiasis-<u>e</u>ctodermal <u>d</u>ystrophy AID - deficiency of activation-induced cytidine deaminase Ataxia-telangiectasia</li><li>CD3-epsilon deficiency (causes SCID)</li><li>CD3-gamma deficiency (causes SCID)</li><li>chronic granulomatous disease - deficiency of p47<sup>phox</sup> Phenylketonuria - Phenylalanine hydroxylase (PAH) deficiency Tetrahydrobiopterin deficiencies:
<ul><li>GTP cyclohydrolase I (GTPCH) deficiency</li><li>6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency</li><li>Dihydropteridine reductase (DHPR) deficiency</li><li>Pterin-4a-carbinolamine dehydratase (PCD) deficiency</li></ul></li><li>Janus Kinase 3 (JAK3) deficiency (causes SCID)</li><li>Hereditary fructose intolerance<!-- EPO <DP n="43"> --></li><li>Porphyria (one of the six forms is caused by a recessive gene)</li><li>Sickle Cell Anemia</li><li>Tay Sachs syndrome</li><li>Thalassemia</li><li>Wilson's disease</li><li>Xeroderma pigmentosum</li><li>Zeta-chain-associated protein kinase deficiency (causes SCID)</li></ul></p><p id="p0084" num="0084">The totipotent and/or pluripotent stem cell lines having a homozygous recessive disease-causing gene that are produced by the methods of the present invention are highly useful. They can be cultured under conditions in which they differentiate into cell types related to manifestation of the disease phenotype. Such cells having a homozygous recessive disease-causing gene are useful for basic research directed to studying the disease phenotype ex vivo. They can also be implanted into experimental animals (e.g., immunodeficient animals), for study of their metabolic activities in vivo. Persons skilled in the art would recognize that studies in which such cells are genetically modified can be useful for gaining understanding of the disease phenotype. Such cells having a homozygous recessive disease-causing gene can also be used in drug discovery; e.g., in screening for drugs or other therapies that will treat or cure the disease caused by the recessive gene.</p><p id="p0085" num="0085">In order to further illustrate the invention and its preferred embodiments, the following examples are provided. These examples are intended to be exemplary and in no way limitative of the scope of the present invention.<!-- EPO <DP n="44"> --></p><heading id="h0025">EXAMPLE 1</heading><heading id="h0026"><u>Production of Parthogenic Primate Primordial Stem Cells (PPSC's)</u></heading><heading id="h0027">Materials and Methods</heading><p id="p0086" num="0086"><ol><li>1. Cynomolgous Monkey (Macaca fascicularis) were superovulated using a single injection of 1000 IU of pregnant mare's serum gonadrophin (PMSG) and 500 IU of human chorionic gonadoprophin (hCG) four days later.</li><li>2. Ovaries were retrieved by laparotomy and oocytes dissected from the follicles and placed in maturation media 36 to 48 hrs after (hCG). Maturation media consisted of medium-199 (Gibco BRL) with Earle's balanced salt solution supplemented with 20% fetal bovine serum, 10 IU/ml of PMSG, 10 IU/ml of hCG, 0.05 mg/ml of penicillin G and 0.075 mg/ml of steptomycin sulfate (Hong, 1999).</li><li>3. Oocyte activation After 40 hrs in maturation, metaphase II eggs were placed in 10 micromoles of lonomycin followed incubation in 200 mM 6-DMAP (dimethylaminopurine) for 3 to 4 hrs.</li><li>4. Embryo culture. Commercially available embryo culture media 'Cooks' was used (modified SOF). Embryos were cultured with a co-culture of mitotically inactivated mouse embryonic fibroblasts as feeder layer.</li><li>5. Isolation of inner cell mass
<ol><li>a) Upon development to blastocyst, embryos were placed in a buffered solution of 0.3% pronase for 2 minutes to digest zona pellucida</li><li>b) Blastocyts were then rinsed in buffered solution and moved to solution of G1 culture media and polyclonal antibodies (antihuman whole serum) 1:3 dilution for 30 minutes.</li><li>c) Embryos were rinsed 5 times in a buffered solution.</li><li>d) Embryos were moved into a solution of G1 culture media and guinea pig complement 1:3 dilution for 30 minutes.<!-- EPO <DP n="45"> --></li><li>e) Remaining of the embryos (dead trophoblast cells and ICM) wee rinsed 5 times in buffered solution the Inner Cell Mass (ICM) was isolated and placed on top of a mouse embryonic fibroblast feeder layer for isolation and growth of Primordial Stem Cells (PSC's).</li></ol></li></ol></p><heading id="h0028"><u>Results</u></heading><p id="p0087" num="0087">We have obtained 450 eggs total, after maturation, 224 were still at germinal vesicle stage (GV = no maturation), 79 were dead, 56 were at metaphase one (MI) and 91 at metaphase two (MII).</p><p id="p0088" num="0088">We have parthenogenically activated all of them. As expected, there was no cleavage on the GV group, 32% cleavage on the MI and 57% on the MII. When put in culture, 7 embryos developed to the blastocyst stage (See <figref idrefs="f0001">Figure 1</figref>).</p><p id="p0089" num="0089">After attempting to establish ES-like culture cells, four Inner cell masses attached nicely one differentiated immediately, and out of the three remaining, one cell line was obtained. This cell line is called Cyno 1 (<figref idrefs="f0002">Fig. 2</figref>). This cell line before and after immunosurgery is shown in <figref idrefs="f0003">Figures 3</figref> and <figref idrefs="f0004">4</figref>. <figref idrefs="f0005">Figure 5</figref> shows the Cyno 1 Cell line five days after plating.</p><p id="p0090" num="0090"><figref idrefs="f0006">Figure 6</figref> shows the Cyno 1 cell line growing on top of a mouse fibroblast feeder layer. These cells show typical morphology of pluripotent-embryonic-cells such as small nuclear cytoplasmic ration and the presence of cytoplasmic granules.</p><p id="p0091" num="0091">These cells were maintained in an undifferentiated state for a period of months. This is evidenced by screening of such cells after prolonged culturing for the expression of a cell marker characteristic of undifferentiated cells, Alkaline Phosphatase. As expected, cells were positive on passage 3 and on passage 5.</p><p id="p0092" num="0092">The fact that these cells maintain their pluripotency is also shown by their spontaneous differentiation into many differentiated cell types after being placed in tissue culture in the absence of a feeder layer. In the days following, the cells were observed to differentiate into cuboidal epithelium,<!-- EPO <DP n="46"> --> fibroblasts, beating myocardial cells and other cells. Two colonies of beating myocardial cells wee observed in one well of a 4-well tissue culture plate.</p><p id="p0093" num="0093">To determine whether differentiated cells of various somatic cell lineages were observed from the differentiating PPSC's, we extracted mRNA from differentiated cell cultures, performed RT-PCR, using human sequence primers specific for various differentiated cell types. As shown in <figref idrefs="f0006">figure 6</figref>, transcripts of a predicted size for the mesodermally-derived transcripts brachyury and skeletal muscle myosin heavy polypeptide 2 were observed. The transcript sonic hedgehog essential for endoderm development was observed. In addition, the neuron-specific ectoderm marker enolase was observed as well as keratin (not shown) as markers of ectodermally derived cells. These PCR products were not observed in the mouse feeder layer controls or in the absence of reverse transcriptase.</p><p id="p0094" num="0094">To establish that the imprinting status of parthogenetic PPSC's different than that of di-parental PPSCs we looked at the expression of several imprinted genes. Genes that are mono-allelically expressed from the paternal allele, would not be expected to be expressed in parthogenetic cells, as these cells are derived exclusively from the maternal genome. The <i>Snrpn</i> gene is mono-allelically expressed from the paternal allele in mouse blastocyst inner cell mass [<nplcit id="ncit0025" npl-type="s"><text>Szabo,PE and Mann, JR; Genes &amp; Development 9:3097-3108 (1995</text></nplcit>)]. We looked at the expression of this gene in the parthogenetic <i>Macaca facicularis</i> PPSCs and found that the express was undetectable by RT-PCR, whereas under identical conditions, this gene is readily detected in fibroblast cell cultures from the same species. The <i>Snrpn</i> gene is expected to be expressed in diparental PPSCs, as these cells contain a paternal allele. In <figref idrefs="f0007">Figure 7</figref>, the expected size RT-PCR product for the <i>Snrpn</i> gene is 260 bp.<!-- EPO <DP n="47"> --></p><heading id="h0029"><u>EXAMPLE 2</u></heading><heading id="h0030"><u>Stable Engraftment of Homozygous Fibroblasts in Histocompatible are Non-Histocompatible Cynomolgous Recipients</u></heading><p id="p0095" num="0095">Connective tissue fibroblasts are generated from the cyno-1 stem cell line described above which are labeled with green flourescent protein (GFP) gene. This cell line is homozygous as evidenced by the portion of a single allete of 225 basepairs using a primer set specific for DQBlu6011-17. These cells are propogated in vitro until several million cells are obtained.</p><p id="p0096" num="0096">Thereafter, approximately a million labeled connective fibroblasts are transplanted into histocompatible cynomolyus monkey recipients, and non-histocompatible cynomolgous controls. Each monkey is transplanted with a million labeled cells administered by injection in the upper arm at for different sites, in four equal parts.</p><p id="p0097" num="0097">The degree of engraftment of these engrafted labeled cells is assessed at three different times, at four weeks, six months and a year. Three of the four grafts are removed at three different times and the number of GFP labeled cells is determined in the histocompatible transplant recipients and controls. The number of GFP cells is compared for both groups.</p><p id="p0098" num="0098">Also, a histological examination is effected to look for any signs of lymphocyte infiltration and any signs of rejection.</p><heading id="h0031"><u>EXAMPLE 3</u></heading><heading id="h0032"><u>Production of Homozygous Stem Cell Lines from Rabit Parthenogenically Activated Ooyctes</u></heading><p id="p0099" num="0099">Rabbit ES cells were similarly obtained from parthenogenetic embryos. Specifically, rabbit oocytes were obtained from superovulating rabbits and were acttuated using ionomycin and DMAP. This resulted in blastocystes, the inner cell masses of which were transferred to fibroblast factor layer. This in turn resulted in the production of rabbit ES cell lines which stained positive for<!-- EPO <DP n="48"> --> characteristic embryonic antigens and which gave rise to various differentiated cell types when removed from the front layer.</p><p id="p0100" num="0100">More specifically, true rabbit ES cell lines morphlogically looked like ES cells and differentiated into into all three germ cell linenages. Among the cell types that observed from this cell line were myocordial, vascular endothalial, neuronal, and hemotopoiath cell lineages.</p><heading id="h0033"><u>EXAMPLE 4</u></heading><heading id="h0034"><u>Protection of Homozygous Stem Cell Lines from Human Parthenogenically Activated Oocytes</u></heading><p id="p0101" num="0101"><u>Production of Autologous Cells by Parthenogenetic Activation of Oocytes</u></p><p id="p0102" num="0102">Oocytes from three volunteers were used for parthenogenetic activation. The donors were induced to superovulate by 11 days of low dose (75 IU bid) gonadotropin injections prior to hCG injection. A total of 22 oocytes were obtained from the donors 34 hours after HCG stimulation, and were activated at 40-43 h after hCG stimulation.</p><p id="p0103" num="0103">The oocytes ere activated on day 0, using the ionomycin/DMAP activation protocol described above. Twelve hours after activation, 20 oocytes (90%) developed one pronucleus and cleaved to the two-cell to four-cell stage on day 2. On day 5 of culture, evident blastocoele cavities were observed in six of the parthenotes (30% of the cleaved oocytes) though none of the embryos displayed a clearly discernible inner cell mass. The results of parthenogenetic activation of the human oocytes are summarized in Table 4.<!-- EPO <DP n="49"> -->
<tables id="tabl0004" num="0004"><table frame="bottom"><title>Table 4, Parthenogenetic Activation of Human Oocytes</title><tgroup cols="5" colsep="0"><colspec colnum="1" colname="col1" colwidth="18mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="24mm"/><colspec colnum="5" colname="col5" colwidth="56mm"/><thead><row><entry valign="top">Donor</entry><entry valign="top">No. of Oocytes</entry><entry valign="top">Pronucleus (%)<sup>a</sup></entry><entry valign="top">Cleaved (%)<sup>a</sup></entry><entry valign="top">Embryos with blastocoele Cavity (%)<sup>5</sup></entry></row></thead><tbody><row><entry>1</entry><entry>5</entry><entry>4(80)</entry><entry>4(80)</entry><entry>0</entry></row><row><entry>2</entry><entry>14</entry><entry>13(93)</entry><entry>13(93)</entry><entry>4(31)</entry></row><row><entry>6</entry><entry>5</entry><entry>3</entry><entry>3(100)</entry><entry>2(67)</entry></row><row><entry>Total</entry><entry>22</entry><entry>20(90)</entry><entry>20(90)</entry><entry>6(30)</entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="18mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="24mm"/><colspec colnum="5" colname="col5" colwidth="56mm"/><tbody><row><entry namest="col1" nameend="col5" align="justify"><sup>a</sup> As a percentage of activated oocytes.<br/>
<sup>b</sup> As percentage of cleaved oocytes.</entry></row></tbody></tgroup></table></tables></p><p id="p0104" num="0104"><figref idrefs="f0008">Figure 8</figref> shows MII oocytes at the time of retrieval. <figref idrefs="f0009">Figure 9</figref> shows four-to six-cell embryos 48 h after activation. Distinguishable single-nucleated blastomeres (labeled "n" in <figref idrefs="f0006">Fig. 6</figref>) were consistently observed. <figref idrefs="f0010">Figure 10</figref> shows embryos with blastocoele cavities (arrows) that were detected on day 6 and maintained in culture until day 7. The scale bars for <figref idrefs="f0006 f0007 f0008">Figures 6 - 8</figref> = 100 µm.</p><p id="p0105" num="0105">In a study similar to the one described above, human oocytes were activated using the ionomycin/DMAP activation protocol and were cultured in <i>vitro.</i> One of the activated embryos developed a pronucleus, cleaved, formed a blastocoele cavity, and then developed into a blastocyst having an inner cell mass, shown in <figref idrefs="f0011">Figure 11</figref>. The inner cell mass was isolated and plated on mouse feeder layers as described (<nplcit id="ncit0026" npl-type="s"><text>Cibelli, J.B., et al. 2002. Parthenogenetic stem calls in non-human primates. Science 295: 819</text></nplcit>). The cultured ICM cells increased in number over the first week, and cells indistinguishable from human embryonic stem cells were observed. These grew in close association as a colony with a distinct boundary, as shown in <figref idrefs="f0012">Figure 12</figref>; they had a high nuclear-to-cytoplasmic ratio, prominent nucleoli, and were observed to differentiate <i>in vitro</i> into multiple differentiated cell types.<!-- EPO <DP n="50"> --></p><heading id="h0035"><u>EXAMPLE 5</u></heading><heading id="h0036"><u>Production of Homozygous Stem Cell Lines from Mouse Parthenogenically Activated Oocytes</u></heading><p id="p0106" num="0106">Using substantially the same methods described in the present application, another research group, <nplcit id="ncit0027" npl-type="s"><text>Lin et al., Stem Cells 21:152-161 (2003</text></nplcit>) incorporated by reference in its entirety, generated stem cell lines from unfertilized mouse metaphase II oocytes. These oocytes were activated by 5 minute exposure to 5mm calcium ionophore (ionomycin) followed by a 3 hour exposure to 6-methyldiaminopurine (DMAP). Those stem cell lines were characterized as stem cell lines based on their expression of characteristic embryonic antigens (SSEAs, OCT-4, alkaline phosphatase and telomerase) and their pluripotency (give rise to ectodermal, endodermal and mesodermal cell types).</p><p id="p0107" num="0107">Specifically, activated, unertilized oocytes from F1 hybrid mice (H-2-B/D0 were used to establish those stem cell lines homozygous for H-2-B and H-2-D respectively. The stem cell lines appeared karyotypically normal. When cultured in vitro in the pressures of specific growth factors, these cell lines gave rise to ectodermal, mesodermal, and enodermal cell types. Histological examination of cultures revealed cells having the morphology of neuronal cells and hemotopviette lineages (lymphocytes, monocytes and erythrocytes).</p><p id="p0108" num="0108">Further, when these cell lines were implanted in the kidney of syngenetic F1 mice they similarly resulted in teratomas that comprised cells of all three germ layers. The teratemas when histologically examined showed evidence of hair follicles, thyroid glands, lung epithelium and connective tissue.</p><heading id="h0037"><u>CONCLUSIONS</u></heading><p id="p0109" num="0109">The results in the foregoing examples provides proof of principle, namely that homozygous stem cell lines may be generated from embryos,<!-- EPO <DP n="51"> --> e.g. parthenogenically activated embryos, and used to produce differentiated cell types for cell therapy. More specifically, the present instruction provides methods for making libraries or banks of stem cell lines that are homozygous for specific MHC alleles. Thereby, a bank of cells is available which can be used to produce differentiated cells which are histocompatible for a wide range of transplant recipients. This is feasible with a relatively few number of stem cell lines given that certain HLA haplotyes are expressed with relatively high frequency in the human population.</p><p id="p0110" num="0110">These differentiated cells should be well tolerated and be stably engrafted given their antigenic expression relative to the transplant recipient. Also, in the case of stem cell lines derived from parthenogenically activated oocytes, these cells eliminate certain ethical issues with therapeutic cloning, namely a viable embryo (capable of giving rise to an offspring) is never obtained or destroyed. These cells are useful for treating any condition wherein cell or tissue transplantation is therapeutically desirable, e.g. immune deficiencies, age-related deficiencies, cancer, autoimmune disorder, organ deficiencies, disease, or injury, burn, malignancy, cell proliferation disorders, hemotopoietic disorders, e.g. blood malignancy such as non-Hodgkins lymphoma, leukemia, inflamatory disorders, connective tissue disorder, dermatological disorder, ischemia, stroke, neurological disorders and the like. The present cell banks on particularly well suited for treating acute disease, particularly when there is not sufficient time to do therapeutic cloning. For example, those cells are useful in obtaining differentiated cells for treatment of conditions where the patient is near death, <u>e.g.</u>, sepsis, stroke and other conditions where cell therapy is urgently needed. Also, the invention provides means for having cells on hand that express desired therapeutic polypeptides which are histocompatible.<!-- EPO <DP n="52"> --></p><p id="p0111" num="0111">In particular, the invention as described herein provides the following:
<ol><li>1. A stem cell bank comprising a library or plurality of human or non-human animal stem cell lines, each of which is homozygous for at least one MHC allele present in a human or non-human animal population, wherein which each member of said plurality of stem cell lines is homozygous for a different set of MHC alleles relative to the remaining members of the plurality of stem cell lines.</li><li>2. The stem cell bank of clause 1 which is comprised of a plurality of human stem cell lines each member of which is homozygous for a different combination of MHC alleles than the other members of the library.</li><li>3. The stem cell bank of clause 1 which is comprised of at least five different stem cell lines, each member homozygous for a different combination of histocompatibility or MHC antigen alleles.</li><li>4. The human stem cell bank of clause 2 which is comprised of at least five different stem cell lines, each member homozygous for a different combination of histocompatibility or MHC antigen alleles.</li><li>5. The stem cell bank of clause 1 which is comprised of at least ten different stem cell lines each member homozygous for a different combination of histocompatibility or MHC antigen alleles.</li><li>6. The stem cell bank of clause 2 which is comprised of at least ten different stem cell lines each member homozygous for a different combination of histocompatibility or MHC antigen alleles.</li><li>7. The stem cell bank of clause 1 which comprises at least about 100 to 1000 different stem cell lines each homozygous for a different combination of histocompatibility or MHC antigen alleles.</li><li>8. The stem cell bank of clause 1 which is comprised of ES cell lines or inner cell mass derived stem cell lines.</li><li>9. The stem cell bank of clause 8 which is comprised of human ES cell lines.</li><li>10. The human stem cell bank of clause 2 which comprises human stem cell lines that are at least homozygous for the 10 most frequent MHC alleles in the human population.</li><li>11. The human stem cell bank of clause 2 which comprises human stem cell lines that are homozygous for at least the 15 most frequent MHC alleles in the human population.</li><li>12. The human stem cell bank of clause 2 wherein all of the stem cell lines are O-negative.</li><li>13. The human stem cell bank of clause 10 wherein the library includes human stem cells that are homozygous for one or more of the following MHC alleles : HLA-A1, HLA-A2,<!-- EPO <DP n="53"> --> HLA-A3, HLA-A24, HLA-A11, HLA-A28, HLA-A29, HLA-A32, HLA-B15, HLA-B5, HLA-B7, HLA-B8, HLA-B12, HLA-B14, HLA-B18, HLA-835, and HLA-B40.</li><li>14. The human stem cell bank of clause 13 wherein all of said human stem cell lines are O-negative.</li><li>15. The human stem cell bank of clause 13 wherein said stem cell lines are derived from parthenogenic human embryos.</li><li>16. The human stem cell bank of clause 13 wherein said stem cell lines are derived from human nuclear transfer embryos.</li><li>17. The human stem cell bank of clause 13 wherein said stem cell lines are derived from human somatic cells which have been de-differentiated by contacting their DNA with cytoplasm from an oocyte, ES cell, EG cell or another embryonic cell type.</li><li>18. The human stem cell bank of clause 2 which is produced from human embryos derived from an artificially haploidized somatic cell.</li><li>19. The human cell bank of clause 2 which includes at least one human stem cell line which is rendered homozygous for an MHC allele by removal of one or more MHC alleles by knockout or RNA interference.</li><li>20. The human cell bank of clause 10 which includes stem cell lines which are homozygous for at least one of the following HLA-A, HLA-B and HLA-DR haplotype combinations: 1, 7, 2; 1, 8, 3; 2, 14, 1; 2, 35, 4; 2, 35, 8; 2, 44, 4; 3, 7, 2; 3, 7, 4; 3, 7, 8; 3, 35, 1; 31, 51, 4; and 32, 14, 7.</li><li>21. The human stem cell bank of clause 20 which contains cell lines homozygous for all of said HLA-A, HLA-B and HLA-DR haplotype combinations.</li><li>22. The human stem cell bank of clause 20 which is O-negative.</li><li>23. The human stem cell bank of clause 21 which is O-negative.</li><li>24. The human stem cell bank of clause 19 which the cells are rendered homozygous by the removal of one set of MHC alleles by knockout or RNA interference and the addition of another homozygous set of MHC alleles.</li><li>25. The stem cell bank of clause 1, which contains lines of stem cells selected from the group consisting of totipotent, nearly totipotent, and pluripotent stem cells.</li><li>26. The stem cell bank of clause 1, which contains a plurality of lines of embryonic stem cells.</li><li>27. The stem cell bank of clause 1, which contains a plurality of lines of stem cells that can differentiate into hematopoietic stem cells.<!-- EPO <DP n="54"> --></li><li>28. The stem cell bank of clause 1, which contains a plurality of lines of hematopoietic stem cells.</li><li>29. The stem cell bank of clam 1, which contains a plurality of lines of stem cells that can differentiate into vascular endothelial precursor cells.</li><li>30. The stem cell bank of clause 1 which contain a plurality of stem cells that can differentiate into myocardial cells.</li><li>31. The stem cell bank of clause 1, which contains a plurality of stem cells that can differentiate into hepatic cells.</li><li>32. The stem cell bank of clause 1, which contains a plurality of stem cells that can differentiate into pancreatic beta cells.</li><li>33. The stem cell bank of clause 2, which contains a stem cell line homozygous for an MHC allele selected from HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP, wherein the cells are of the O-negative blood group.</li><li>34. The stem cell bank of clause 2, which contains a stem cell line homozygous for the MHC alleles encoding HLA-A, HLA-B, and HLA-DR.</li><li>35. The stem cell bank of clause 2, which contains a stem cell line homozygous for the MHC alleles encoding HLA-A, HLA-B, and HLA-DR, wherein the cells are of the O-negative blood group.</li><li>36. The stem cell bank of clause 1, which contains lines of stem cells derived from embryos produced by in vitro fertilization or intracytoplasmic sperm injection.</li><li>37. The stem cell bank of clause 1, which contains lines of diploid stem cells derived from embryos produced by parthenogenesis.</li><li>38. The stem cell bank of clause 37, which contains lines of diploid stem cells in which all of the MHC alleles are homozygous.</li><li>39. The stem cell bank of clause 1, which contains lines of stem cells derived from embryos produced by cloning by same or cross-species nuclear transfer.</li><li>40. The stem cell bank of clause 39, which contains at least one line of rejuvenated stem cells.</li><li>41. The stem cell bank of clause 40, wherein the rejuvenated stem cells have telomeres that are on average at least as long as the telomeres of age-matched control cells of the same type that are not generated by nuclear transfer techniques.</li><li>42. The stem cell bank of clause 41, wherein the proliferative life-span of the rejuvenated stem cells is at least as long as the proliferative life-span of age-matched control cells of the same type that are not generated by nuclear transfer techniques.<!-- EPO <DP n="55"> --></li><li>43. The stem cell bank of clause 41, wherein the proliferative life-span of the rejuvenated stem cells is longer than the proliferative life-span of age-matched control cells of the same type that are not generated by nuclear transfer techniques.</li><li>44. The stem cell bank of clause 41, wherein EPC-1 activity in the rejuvenated stem cells is greater than EPC-1 activity in age-matched control cells of the same type that are not generated by nuclear transfer techniques.</li><li>45. The stem cell bank of clause 41, wherein telomerase activity in rejuvenated stem cells is greater than telomerase activity in age-matched control cells of the same type that are not generated by nuclear transfer techniques.</li><li>46. The stem cell bank of clause 40, which contains at least one line of stem cells comprising non-human mitochondria.</li><li>47. The stem cell bank of clause 1, which contains at least one stem cell line that comprises DNA that is genetically modified relative to the DNA of the non-human donor from which the cell line is derived.</li><li>48. The stem cell bank of clause 2, which contains at least one stem cell line that comprises DNA that is genetically modified relative to the human donor from which the cell line is derived.</li><li>49. The stem cell bank of clause 47, wherein the DNA of the genetically altered stem cell line is modified by adding, modifying, substituting, or deleting one or more DNA sequences.</li><li>50. The human stem cell bank of clause 48, which the DNA or the genetically altered stem cell line is modified by adding, modifying, substituting or deleting one or more DNA sequences.</li><li>51. The stem cell bank of clause 49, wherein the DNA of the genetically altered stem cell line is modified so as to obtain, increase, decrease, inhibit, or otherwise modify, the expression of a gene that is native to, or introduced into, cells of the at least one cell line, relative to expression of said gene in a control cell without the genetic modification.</li><li>52. The stem cell bank of clause 49, wherein the DNA of the genetically altered stem cell line is modified so as to obtain, increase, decrease, inhibit, or otherwise modify, the expression of a gene that is native to, or introduced into, cells of the at least one cell line, relative to expression of said gene in a control cell without the genetic modification.</li><li>53. The stem cell bank of clause 51, wherein the DNA of the genetically altered stem cell line is modified by homologous recombination.</li><li>54. The human stem cell bank of clause 52, wherein the DNA or the genetically altered stem cell line is modified by homozygous recombination.<!-- EPO <DP n="56"> --></li><li>55. The stem cell bank of clause 51, wherein the DNA of the genetically altered stem cell line is altered to prevent the expression of a gene encoding an antigenic protein that elicits an immune response contributing to rejection.</li><li>56. The stem cell bank of clause 51, wherein the DNA of the genetically altered stem cell line is altered to prevent the expression of a gene encoding an antigenic protein that elicits an immune response contributing to rejection.</li><li>57. The stem cell bank of clause 51, wherein the DNA of the genetically altered stem cell line is altered to express a gene that inhibits the immune rejection of that cell.</li><li>58. The stem cell bank of clause 51, wherein the DNA of the genetically altered stem cell line is altered to express a gene that inhibits the immune rejection of that cell.</li><li>59. The stem cell bank of clause 56, wherein the DNA of the genetically altered stem cell line is modified so as to inhibit production of at least one HLA antigen by cells of said cell line.</li><li>60. The stem cell bank of clause 59, wherein the DNA of the genetically altered stem cell line is modified so as to inhibit production of one or more HLA antigens selected from HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP.</li><li>61. The stem cell bank of clause 55, wherein the DNA of the genetically altered stem cell line is modified so as to inhibit production of β2-microglobulin.</li><li>62. The stem cell bank of clause 47, wherein the DNA of the genetically altered stem cell line is altered by replacing a non-homozygous MHC allele with one that is homozygous.</li><li>63. A method for treatment, preferably acute treatment, comprising transplanting cells or tissue that are homozygous for at least one HLA allele in a person in need of such a transplant, comprising:
<ol><li>a. identifying the MHC alleles of a person in need of a transplant (the recipient);</li><li>b. obtaining from a stem cell bank comprising a plurality of stem cells homozygous for at least one MHC allele of the transplant recipient;</li><li>c. generating cells or tissue suitable for transplant from said stem cells; and</li><li>d. transplanting said cells or tissue suitable for transplant into said recipient.</li></ol></li><li>64. The method of clause 63 wherein said stem cell bank comprises at least 10 different human stem cell lines, wherein each of said stem cell lines are homozygous for a different combination of HLA alleles relative to the other stem cell lines.</li><li>65. The method of clause 63 wherein said stem cell bank comprises at least 15 different human stem cell lines wherein each of said stem cell lines are homozygous for a different combination of HLA alleles relative to the other human stem cell lines in the cell bank.<!-- EPO <DP n="57"> --></li><li>66. The method of clause 63 wherein said stem cell bank comprises at least about 100 to 1000 stem cell lines each homozygous for a different combination of HLA alleles relative to the other human stem cell lines in the cell bank.</li><li>67. The method of clause 63 wherein one or more of said human stem cell lines are ES or inner cell mass-derived stem cells.</li><li>68. The method of clause 63 wherein one or more of said human stem cell lines is derived from a parthenogenetic human embryo.</li><li>69. The method of clause 63 wherein one or more of said human stem cell lines are produced by haploidization comprising the steps of
<ol><li>a) inserting or fusing a somatic donor cell or nucleus thereof into or with an oocyte which is treated to remove or destroy its endogenous genomic DNA before, during or after insertion or fusion;</li><li>b) activation of the reconstructed embryo to expel haploid genome into a pseudopolar body;</li><li>c) screening of the pseudopolar body for the genetype of the remaining pronuclear;</li><li>d) combination of the two pronuclei to generate a reconstructured diploid embryo by pronuclear transfer or alternatively producing a diploid embryo by transferral of a pronucleus to an activated haploid oocyte comprising desired haploid genome;</li><li>e) optionally injecting human morula stage embryo lysates into the reconstructed embryos; and</li><li>f) isolating human stem cell lines from said reconstructed diploid embryo.</li></ol></li><li>70. The method of clause 63 wherein one or more of said human stem cell lines is produced by the insertion of first and second polar bodies into a recipient cell.</li><li>71. The method of clause 63 wherein at least one of said stem cell lines is produced by de-differentiation of a somatic cell by cytoplasmic transfer.</li><li>72. The method of clause 63 wherein said human stem cell bank comprises cells which are homozygous for one of the following HLA serotypes: HLA-A1, HLA-A3, HLA-A11, HLA-A15, HLA-A22, HLA-A27, HLA-A28, HLA-A29, HLA-A32, HLA-B5, HLA-B7, HLA-B8, HLA-B12, HLA-B 17, HLA-B 18, HLA-B35 and HLA-B40.</li><li>73. The method of clause 63 wherein said human stem cell bank comprises stem cells which are homozygous for at least one of the following HLA-A, -B or-DR haplotypes : 1, 7, 2; 1, 8, 3; 2, 14, 1; 2, 35, 4; 2, 35, 8; 2, 44, 4; 3, 7, 2; 3, 7, 4; 3, 7, 8; 3, 35, 1; 31, 51, 4; and 32, 14, 7.</li><li>74. The method of clause 72 wherein said cell lines are O-negative.<!-- EPO <DP n="58"> --></li><li>75. The method of clause 73 wherein said cell lines are O-negative.</li><li>76. The method of clause 63, wherein step b comprises obtaining stem cells selected from the group consisting of totipotent, nearly totipotent, and pluripotent stem cells.</li><li>77. The method of clause 63, wherein step b comprises obtaining embryonic stem cells.</li><li>78. The method of clause 63, wherein step b comprises obtaining stem cells that can differentiate into hematopoietic stem cells.</li><li>79. The method of clause 63, wherein step b comprises obtaining hematopoietic stem cells from the stem cell bank.</li><li>80. The method of clause 63, wherein step b comprises obtaining stem cells homozygous for an MHC allele selected from HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP.</li><li>81. The method of clause 63, wherein step b comprises obtaining stem cells homozygous for the MHC alleles encoding HLA-A, HLA-B, and HLA-DR.</li><li>82. The method of clause 63, wherein step b comprises obtaining stem cells derived from embryos produced by in vitro fertilization or intracytoplasmic sperm injection.</li><li>83. The method of clause 63, wherein step b comprises obtaining diploid stem cells derived from embryos produced by parthenogenesis.</li><li>84. The method of clause 83, comprising obtaining diploid stem cells in which all of the MHC alleles are homozygous.</li><li>85. The method of clause 63, wherein step b comprises obtaining stem cells derived from embryos produced by cloning by nuclear transfer.</li><li>86. The method of clause 85, comprising obtaining rejuvenated stem cells.</li><li>87. The method of clause 86, comprising obtaining rejuvenated stem cells having telomeres that are on average at least as long as the telomeres of age-matched control cells of the same type that are not generated by nuclear transfer techniques.</li><li>88. The method of clause 86, comprising obtaining rejuvenated stem cells for which the proliferative life-span is at least as long as the proliferative life-span of age-matched control cells of the same type that are not generated by nuclear transfer techniques.</li><li>89. The method of clause 86, comprising obtaining rejuvenated stem cells for which the proliferative life-span is longer than the proliferative life-span of age-matched control cells of the same type that are not generated by nuclear transfer techniques.<!-- EPO <DP n="59"> --></li><li>90. The method of clause 86, comprising obtaining rejuvenated stem cells having EPC-1 activity that is greater than EPC-1 activity in age-matched control cells of the same type that are not generated by nuclear transfer techniques.</li><li>91. The method of clause 86, comprising obtaining rejuvenated stem cells having telomerase activity that is greater than telomerase activity in age-matched control cells of the same type that are not generated by nuclear transfer techniques.</li><li>92. The method of clause 85, comprising obtaining stem cells comprising non-human mitochondria.</li><li>93. The method of clause 63, wherein step b comprises obtaining stem cells having DNA that is genetically modified relative to the DNA of the human donor from which the stem cells are derived.</li><li>94. The method of clause 93, comprising obtaining genetically altered stem cells, the DNA of which is modified by adding, modifying, substituting, or deleting one or more DNA sequences.</li><li>95. The method of clause 93, comprising obtaining genetically altered stem cells, the DNA of which is modified so as to obtain, increase, decrease, inhibit, or otherwise modify, the expression of a gene that is native to or introduced into said cells, relative to expression of said gene in a control cell without the genetic modification.</li><li>96. The method of clause 93, comprising obtaining genetically altered stem cells, the DNA of which is modified by homologous recombination.</li><li>97. The method of clause 93, comprising obtaining genetically altered stem cells, the DNA of which is altered to prevent the expression of a gene encoding an antigenic protein that elicits an immune response contributing to rejection.</li><li>98. The method of clause 96, comprising genetically altered stem cells, the DNA of which is modified so as to inhibit production of at least one HLA antigen by cells of said cell line.</li><li>99. The method of clause 96, comprising genetically altered stem cells, the DNA of which is modified so as to inhibit production of one or more HLA antigens selected from HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP.</li><li>100. The method of clause 96, comprising genetically altered stem cells, the DNA of which is modified so as to inhibit production of β2-microglobulin.</li><li>101. The method of clause 96, comprising genetically altered stem cells, the DNA of which is altered by replacing a non-homozygous MHC allele with one that is homozygous.</li><li>102. A method for producing stem cells homozygous for at least one MHC allele present in a human population, comprising:
<ol><li>a) obtaining oocytes from a donor;<!-- EPO <DP n="60"> --></li><li>b) activating the oocytes;</li><li>c) exposing the activated oocytes to chemical treatment that inhibits extrusion of the second polar body;</li><li>d) culturing the embryo in vitro under conditions resulting in formation of a blastocyst;</li><li>e) culturing inner cell mass cells of the blastocyst in vitro under conditions resulting in production of stem cells; and</li><li>f) screening to identify stem cells homozygous in a particular MHC allele.</li></ol></li><li>103. The method of clause 102 wherein said stem cells are human.</li><li>104. The method of clause 102 wherein said method is repeated with oocytes from different donors and a bank or library of different stem cell lines which are homozygous for different MHC alleles relative to the other members in the group are obtained.</li><li>105. The method of clause 102 wherein said stem cell lines are human.</li><li>106. The method of clause 105 wherein said stem cell lines are O-negative.</li><li>107. The method of clause 104 wherein said stem cell bank includes stem cell lines which are homozygous for one or more of the following HLA serotypes: HLA-A1, HLA-A3, HLA-A11, HLA-A15, HLA-A22, HLA-A24, HLA-A28, HLA-A29, HLA-A32, HLA-B5, HLA-B7, HLA-B8, HLA-B12, HLA-B17, HLA-B18, HLA-B35 AND HLA-840.</li><li>108. The method of clause 105 wherein said stem cell bank includes stem cell lines which are homozygous for at least one of the following HLA-a, -B and-DR haplotypes : 1, 7, 2; 1, 8, 3; 2, 14, 1; 2, 35, 4; 2, 35, 8; 2, 44, 4; 3, 7, 2; 3, 7, 4; 3, 7, 8; 3, 35, 1; 31, 51, 4 and 32, 14, 7.</li><li>109. The method of clause 106 wherein said stem cell lines are O-negative.</li><li>110. The method of clause 107 wherein said stem cell lines are O-negative.</li><li>111. The method of clause 102, wherein the stem cells are totipotent, nearly totipotent, or pluripotent stem cells.</li><li>112. The method of clause 102, wherein the stem cells can differentiate into hematopoietic stem cells.</li><li>113. The method of clause 102, wherein the stem cells are homozygous for an MHC allele selected from HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP.</li><li>114. The method of clause 102, wherein the stem cells are homozygous for the MHC alleles encoding HLA-A, HLA-B, and HLA-DR.<!-- EPO <DP n="61"> --></li><li>115. A diploid cell line that is parthenogenetically-derived and is homozygous for at least one recessive disease-causing allele.</li><li>116. The parthenogenetically-derived cell line of clause 115, which is a line of stem cells.</li><li>117. The diploid cell line of clause 116 which is human.</li><li>118. The diploid cell line of clause 116 which is murine.</li><li>119. The parthenogenetically-derived stem cell line of clause 116, which is a line of totipotent, nearly totipotent, or pluripotent stem cells.</li><li>120. The parthenogenetically-derived stem cell line of clause 116, which is a line of embryonic stem cells.</li><li>121. The parthenogenetically-derived cell line of clause 116, which is a line of cells that are homozygous for at least one recessive disease-causing allele causing a pathological condition selected from the group consisting of Adenosine deaminase deficiency, Albinism, Adenylosuccinate lyase deficiency, Alpha-1 antitrypsin deficiency, Cystic Fibrosis, Friedreich's ataxia, Gaucher's disease, hypercholesterolemia, Alzheimer's Disease, <u>A</u>utoimmune <u>p</u>olyendocrinopathy <u>c</u>andidiasis-<u>e</u>ctodermal <u>d</u>ystrophy. deficiency of activation-induced cytidine deaminase, Ataxia-telangiectasia, severe combined immunodeficieny (SCID), chronic granulomatous disease, Phenylketonuria, Tetrahydrobiopterin deficiency, Hereditary fructose intolerance, Porphyria (one of the six forms is caused by a recessive gene), Sickle Cell Anemia, Tay Sachs syndrome, Thalassemia, Wilson's disease, and Xeroderma pigmentosum.</li><li>122. A method for producing stem cells homozygous for at least one recessive disease-causing allele, comprising:
<ol><li>a) obtaining oocytes from a donor whose DNA contains a recessive disease-causing allele;</li><li>b) activating the oocytes;</li><li>c) exposing the activated oocytes to chemical treatment that inhibits extrusion of the second polar body;</li><li>d) culturing the embryo in vitro under conditions resulting in formation of a blastocyst;</li><li>e) culturing inner cell mass cells of the blastocyst in vitro under conditions resulting in production of stem cells; and</li><li>f) screening the stem cells to identify stem cells that are homozygous for a recessive disease-causing allele.</li></ol><!-- EPO <DP n="62"> --></li><li>123. The method of clause 122, wherein step e) results in production of totipotent, nearly totipotent, or pluripotent stem cells.</li><li>124. The method of clause 122, wherein step e) results in production of embryonic stem cells.</li><li>125. The method of clause 122, wherein the stem cells identified in step f) are homozygous for at least one recessive disease-causing allele causing a pathological condition selected from the group consisting of Adenosine deaminase deficiency, Albinism, Adenylosuccinate lyase deficiency, Alpha-1 antitrypsin deficiency, Cystic Fibrosis, Friedreich's ataxia, Gaucher's disease, hypercholesterolemia, Alzheimer's Disease, <u>A</u>utoimmune <u>p</u>olyendocrinopathy <u>c</u>andidiasis-<u>e</u>ctodermal <u>d</u>ystrophy. deficiency of activation-induced cytidine deaminase, Ataxia-telangiectasia, severe combined immunodeficiency (SCID), chronic granulomatous disease, Phenylketonuria, Tetrahydrobiopterin deficiency, Hereditary fructose intolerance, Porphyria (one of the six forms is caused by a recessive gene), Sickle Cell Anemia, Tay Sachs syndrome, Thalassemia, Wilson's disease, and Xeroderma pigmentosum.</li><li>126. The method of clause 122 wherein the stem cells are human.</li><li>127. The method of clause 125 wherein the stem cells are human.</li><li>128. The method of clause 122 wherein said stem cells are used to produce differentiated cells which are used in screening assays to identify molecules that inhibit or block the expression of said recessive disease-causing gene.</li><li>129. The method of clause 128 wherein said screening assays are affected in vitro.</li><li>130. The method of clause 128 wherein said screening assays are affected in a non-human animal that composes said differentiated cells.</li><li>131. A non-human animal model for study of a disease that is caused by the expression of a recessive disease causing gene which is produced by introducing into a non-human animal stem cells according to clause 122 or differentiated cells derived therefrom.</li><li>132. The non-human animal model of clause 131 which is non-human primate.</li><li>133. The non-human animal model of clause 131 which is murine.</li></ol></p></description><claims mxw-id="PCLM56976843" lang="EN" load-source="patent-office"><!-- EPO <DP n="63"> --><claim id="c-en-0001" num="0001"><claim-text>A pluripotent stem cell line that is parthenogenetically-derived produced by the method comprising:
<claim-text>a) providing oocytes from a donor whose DNA contains a recessive disease-causing allele;</claim-text>
<claim-text>b) activating the oocytes;</claim-text>
<claim-text>c) exposing the activated oocytes to chemical treatment that inhibits extrusion of the second polar body;</claim-text>
<claim-text>d) culturing the embryo in vitro under conditions resulting in formation of a blastocyst;</claim-text>
<claim-text>e) culturing inner cell mass cells of the blastocyst in vitro under conditions resulting in production of stem cells; and</claim-text>
<claim-text>f) screening the stem cells to identify stem cells that are homozygous for a recessive disease-causing allele, thereby obtaining a<br/>
homozygous pluripotent stem cell for at least one recessive disease-causing allele.</claim-text></claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The pluripotent stem cell line of claim 1, wherein the cells are human or murine.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The pluripotent stem cell line of claim 1, wherein the at least one recessive disease-causing allele causes a pathological condition selected from the group consisting of Adenosine deaminase deficiency, Albinism, Adenylosuccinate lyase deficiency, Alpha-1 antitrypsin deficiency, Cystic Fibrosis, Friedreich's ataxia, Gaucher's disease, hypercholesterolemia, Alzheimer's Disease, Autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy, deficiency of activation-induced cytidine deaminase, Ataxia-telangiectasia, severe combined immunodeficiency (SCID), chronic granulomatous disease, Phenylketonuria, Tetrahydrobiopterin deficiency, Hereditary fructose intolerance, Porphyria (one of the six forms is caused by a recessive gene), Sickle Cell Anemia, Tay Sachs syndrome, Thalassemia, Wilson's disease, and Xeroderma pigmentosum.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>A method for producing pluripotent stem cells homozygous for at least one recessive disease-causing allele, comprising:
<claim-text>a) providing oocytes from a donor whose DNA contains a recessive disease-causing allele;</claim-text>
<claim-text>b) activating the oocytes;</claim-text>
<claim-text>c) exposing the activated oocytes to chemical treatment that inhibits extrusion of the second polar body;</claim-text>
<claim-text>d) culturing the embryo in vitro under conditions resulting in formation of a blastocyst;</claim-text>
<claim-text>e) culturing inner cell mass cells of the blastocyst in vitro under conditions resulting in production of stem cells; and</claim-text>
<claim-text>f) screening the stem cells to identify stem cells that are homozygous for a recessive disease-causing allele.</claim-text></claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>Pluripotent stem cells produced by the method of claim 4.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>The pluripotent stem cells of claim 5, wherein the stem cells are homozygous for at least one recessive disease-causing allele causing a pathological condition selected from the group consisting of Adenosine deaminase deficiency, Albinism, Adenylosuccinate lyase deficiency, Alpha-1 antitrypsin deficiency, Cystic Fibrosis, Friedreich's ataxia, Gaucher's disease, hypercholesterolemia, Alzheimer's Disease, Autoimmune polyendocrinopathy<!-- EPO <DP n="64"> --> candidiasis-ectodermal dystrophy, deficiency of activation-induced cytidine deaminase, Ataxia-telangiectasia, severe combined immunodeficiency (SCID), chronic granulomatous disease, Phenylketonuria, Tetrahydrobiopterin deficiency, Hereditary fructose intolerance, Porphyria (one of the six forms is caused by a recessive gene), Sickle Cell Anemia, Tay Sachs syndrome, Thalassemia, Wilson's disease, and Xeroderma pigmentosum.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>The pluripotent stem cells of claim 5, wherein the stem cells are human.</claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>The method of claim 4, further comprising differentiation of the pluripotent stem cells.</claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>The method of claim 8, wherein the differentiated cells are used in screening assays to identify molecules that inhibit or block the expression of said recessive disease-causing gene.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>The method of claim 9, wherein said screening assays are affected in vitro.</claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>The method of claim 9, wherein said screening assays are affected in a non-human animal.</claim-text></claim><claim id="c-en-0012" num="0012"><claim-text>A non-human animal model for study of a disease that is caused by the expression of a recessive disease causing gene which is produced by introducing into a non-human animal stem cells according to claim 8 or differentiated cells derived therefrom.</claim-text></claim><claim id="c-en-0013" num="0013"><claim-text>The non-human animal model of claim 12 which is non-human primate or murine.</claim-text></claim><claim id="c-en-0014" num="0014"><claim-text>The cell line of claim 1 or the cells produced by claim 8 for use in a method of transplantation.</claim-text></claim><claim id="c-en-0015" num="0015"><claim-text>Use of the cell line of claim 1 or the cells produced by claim 8 for the manufacture of a medicament for use in transplantation.</claim-text></claim></claims><drawings mxw-id="PDW16667614" load-source="patent-office"><!-- EPO <DP n="65"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="140" he="104" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="66"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="140" he="104" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="67"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="140" he="104" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="68"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="135" he="114" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="69"> --><figure id="f0005" num="5"><img id="if0005" file="imgf0005.tif" wi="135" he="114" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="70"> --><figure id="f0006" num="6"><img id="if0006" file="imgf0006.tif" wi="151" he="148" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="71"> --><figure id="f0007" num="7"><img id="if0007" file="imgf0007.tif" wi="141" he="222" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="72"> --><figure id="f0008" num="8"><img id="if0008" file="imgf0008.tif" wi="153" he="120" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="73"> --><figure id="f0009" num="9B"><img id="if0009" file="imgf0009.tif" wi="153" he="120" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="74"> --><figure id="f0010" num="10"><img id="if0010" file="imgf0010.tif" wi="142" he="132" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="75"> --><figure id="f0011" num="11"><img id="if0011" file="imgf0011.tif" wi="157" he="141" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="76"> --><figure id="f0012" num="12"><img id="if0012" file="imgf0012.tif" wi="157" he="141" img-content="drawing" img-format="tif"/></figure></drawings><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="160" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="158" he="233" type="tif"/><doc-page id="srep0003" file="srep0003.tif" wi="158" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
